

Clustering of strong replicators associated with active promoters is sufficient to establish an early-replicating domain

Caroline Brossas, Anne-Laure Valton, Sergey V Venev, Sabarinadh Chilaka, Antonin Counillon, Marc Laurent, Coralie Goncalves, Bénédicte Duriez, Franck Picard, Job Dekker, et al.

▶ To cite this version:

Caroline Brossas, Anne-Laure Valton, Sergey V Venev, Sabarinadh Chilaka, Antonin Counillon, et al.. Clustering of strong replicators associated with active promoters is sufficient to establish an early-replicating domain. EMBO Journal, 2020, 10.15252/embj.201899520. hal-03023038

HAL Id: hal-03023038

https://hal.science/hal-03023038

Submitted on 25 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Clustering of strong replicators associated with active promoters is sufficient to establish an early-

replicating domain

Caroline Brossas¹, Anne-Laure Valton^{2,5}, Sergey V. Venev², Sabarinadh Chilaka³, Antonin Counillon¹, Marc Laurent¹, Coralie Goncalves¹, Bénédicte Duriez¹, Franck Picard⁴, Job Dekker^{2,5} and Marie-Noëlle Prioleau¹*

¹ Université de Paris, CNRS, Institut Jacques Monod, Equipe Labellisée Association pour la recherche sur

le cancer, Paris, 75013, France

²University of Massachusetts Medical School, Program in Systems Biology, Department of Biochemistry

and Molecular Pharmacology, Worcester, MA 01605, USA

³Present address: Centre for Immunology, University of Glasgow, G12 8QQ, United Kingdom

⁴ Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive UMR

5558, Villeurbanne, France.

⁵ Howard Hughes Medical Institute, Chevy Chase, MD, 20815, USA

* Correspondence: marie-noelle.prioleau@ijm.fr

Abstract

Vertebrate genomes replicate according to a precise temporal program strongly correlated with their

organization into A/B compartments. Until now, the molecular mechanisms underlying the establishment

of early-replicating domains remain largely unknown. We defined two minimal cis-element modules

containing a strong replication origin and chromatin modifier binding sites capable of shifting a targeted

mid-late replicating region for earlier replication. The two origins overlap with a constitutive or a silent

tissue specific promoter. When inserted side-by-side, these modules advance replication timing over a 250

kb region through the cooperation with one endogenous origin located 30 kb away. Moreover, when inserted

at two chromosomal sites separated by 30 kb, these two modules come into close physical proximity and

form an early-replicating domain establishing more contacts with active A compartments. The synergy

depends on the presence of the active promoter/origin. Our results show that clustering of strong origins

located at active promoters can establish early-replicating domains.

1

Keywords: Replication timing/ Replication origin/ Nuclear organization/ Chromatin accessibility/

Promoter

Running title: Formation of an early-replicating domain

Introduction

A precise, cell type-specific temporal program governs the duplication of vertebrate genomes (Ryba et al,

2010). The genome-wide mapping of replication origins with different methods has revealed a high density

of efficient site-specific origins in early-replicated domains, whereas late regions are usually origin-poor

(Prioleau & MacAlpine, 2016). Replication timing (RT) domains are correlated with the organization of

chromosomes into two main types of compartments: compartment A, which is accessible and replicated

early, and compartment B, which is more condensed and replicated late (Ryba et al, 2010). These

compartments, which display greater interaction within themselves rather than across them, were initially

defined by the Hi-C method, at a resolution of 1 megabase (Lieberman-Aiden et al, 2009). The only major

player in the RT program for which the mode of action has been elucidated is Rif1 (Knott et al, 2012;

Yamazaki et al, 2012; Cornacchia et al, 2012). Rif1 has a global repressive effect on genome-wide DNA

replication. This effect is mediated by the recruitment of protein phosphatase 1, which opposes the Dbf4-

dependent kinase (DDK) activity required for origin firing (Hiraga et al, 2014). Consistent with this direct

role, ChIP analyses of Rif1 throughout the mouse genome revealed an overlap between Rif1 associated

domains and late replication (Foti et al, 2016). However, only regions associated with Rif1 but not with the

nuclear lamina switch to early replication in a context of Rif1 depletion. This finding suggests that other

major players, such as the nuclear lamina, are also involved in controlling late replication (Duriez et al,

2019). One key question that remains concerns whether some late-replicating domains are so robustly

constrained by their nuclear compartmentalization that the targeting of a very efficient origin associated

with early timing control elements could not locally advance the timing of their replication. The underlying

2

question is whether a late domain is defined by the deficiency of an early-firing signal together with an accumulation of signals imposing the late-firing of many potential initiation sites. A related question is whether early-replicated domains are defined solely by the absence of a strong negative signal, such as association with the nuclear lamina and/or Rifl. Alternatively, early constant timing regions (CTRs) may result fortuitously from the more or less synchronous firing of a cluster of replicons, each with its own individual local early timing control elements. This hypothesis is supported by the high density of efficient origins mostly associated with transcription start sites (TSS) and thus proximal to sites associated with open chromatin marks in early-replicated domains (Picard *et al*, 2014). In agreement with this model, a recent study showed that stem-cell specific early-replicating domains in mouse are controlled by stem-cell specific *cis*-elements located in promoter and enhancer regions (Sima *et al*, 2019). Moreover, several elements spanning altogether 30 kb had to be deleted so that the early domain switched from early to late, suggesting redundancy between these elements along early domains and their potential capacity to act remotely. Here we put forward the central role of constitutive promoters in the formation of constitutive early-replicating domains and strongly suggests that spatial connections between strong initiation sites play a key role in this fundamental process.

Results

Cooperation between two minimal autonomous replicons impacts on RT at a large scale

The current study is based on the method we developed to quantify the magnitude of the RT shift induced by the insertion of an ectopic DNA sequence into a specific mid-late-replicating locus (chr1:72,565,520 bp, galGal5) (Hassan-Zadeh *et al*, 2012 and Appendix Figure S1). Here we confirmed our previous data on a much larger number of cell lines modified in the same targeted region, allowing a statistical quantification of RT shifts (Figure 1 and Appendix Table S1). The tissue specific β^A -globin promoter containing a strongly active replication origin flanked by 2XFIV (Footprint IV of cHS4 insulator element is a binding site for the Upstream Stimulatory Factor (USF) (West *et al*, 2004)) significantly advanced RT (Figure 1 (ii), *p*-value = 4.57E-05) and to the same extent as the active β -actin constitutive promoter containing an active replication

origin (Figure EV1A) (Figure 1 (iii), p-value = 3.38E-03). Finally, the combination of these two minimal modules $(\beta^A - globin + \beta - actin$ constructs) imposed a stronger shift to earlier replication at the inserted locus than the presence of a single minimal module alone (Figure 1 (iv), p-value = 3.25 E-03 between (ii) and (iv); p-value = 2.66E-03 between (iii) and (iv) and Figure EV1 and Hassan-Zadeh et al, 2012). These endogenous origins/promoters are naturally found in early-replicating domains in DT40 cells (Appendix Figure S2) and therefore constitute excellent models to understand how early domains might be established. Insertion of this large construct on the two homologous chromosomes $(2x (\beta^A-globin+\beta-actin))$ cell line) allowed us to observe a 250 kb region displaying an advance RT compared to a WT cell line (Figure 2A and Appendix Figure S3). A zoom in centred on the site of insertion confirmed that this site is naturally a termination zone (TZ) flanked by two initiation zones (IZ) (Figure 2B). RT profiles obtained from S1 to S4 fractions showed that the IZ about 30 kb upstream of the site of insertion (IZ.1) is activated in S3 in WT cells whereas the IZ located 60 kb downstream (IZ.2) is activated already in S2. IZ.1 and IZ.2 correspond to strong initiation sites detected by the short nascent strand (SNS) assay (Massip et al, 2019). Profiles observed at the same region in a cell line modified on both chromosomes $(2x (\beta^A - globin + \beta - actin))$ cell line) showed firing of the IZ.1 in S1 whereas the IZ.2 is unchanged compared to the WT cell line. Moreover, in this line, IZ.1 is then extended in S2 on the 3' direction towards the insertion site, revealing the activation of origins brought by the inserted construct. These changes led to a 30 kb shift of the TZ downstream of the site of insertion. Overall, this result suggested that the large β^A -globin+ β -actin construct impacted strongly on the RT profile of its surrounding regions in two different ways: it advanced significantly the RT of a 30 kb upstream strong endogenous origin from S3 to S1 and induced strong initiation in S2 due to efficient firing of replication origins present inside the construct.

Two advanced replicons separated by 30 kb synergize to form a synthetic early-replicating region that interacts more with A compartments

Our observation suggested that the large β^A -globin+ β -actin construct might cooperate with endogenous replication origins located about 30 kb upstream. To further test this hypothesis, we inserted two large autonomous replicons 30 kb apart at sites 1 and 3 (insertion site 1; chr1:72,565,520 bp and insertion site 3; chr1: 72,536,061 bp, galGal5, Figure 2B) and tested their impact on RT. The autonomous replicon at site 3 was similar to the one at site 1 except that the gene used conferred puromycin-Nacetyltransferase resistance (PuroR, insertion site 3, Figure 3A). We assessed the impact of RT changes in the middle of our modified region, by introducing a reporter construct in a central position (Insertion site 2; chr1: 72,548,590 bp, galGal5, Figure 2B) between the two autonomous replicons (1+2+3) or on the other chromosome (1+3) (Figure 3A). The reporter construct consisted of the erythroid-specific β^A -globin origin/promoter linked to the green fluorescent protein (GFP) reporter gene and a 1.6 kb fragment of human chromosome 7 (h.K7; chr7:26,873,165-26,874,805 bp, hg38) containing no replication origin (Figure 3A). We found that the GFP reporter construct had no impact on RT when inserted alone at site 2 (- ΔL + ΔE = -5.1%, Figure EV2A). We then showed that the β^A -globin+ β -actin construct inserted at site 1 had similar effects on RT when associated with GFP reporter construct insertion at site 2 on the same or the other chromosome (compare Figure EV1B with Figure EV2B and C and Hassan-Zadeh et al, 2012). These results confirm the neutral impact on RT of inserting the GFP reporter construct at site 2. We then investigated whether the insertion of a single autonomous replicon at site 3 was able to advance RT as efficiently as insertion at site 1. We confirmed that the β^A -globin+ β -actin construct induced a substantial shift in RT when inserted at this new genomic position ($-\Delta L + \Delta E = +26.8\%$ for clone 1 and $-\Delta L + \Delta E = +22\%$ for clone 2, Figure EV2D). This shift was similar to the one observed in β^A -globin+ β -actin clones after insertion at site 1 (pvalue = 0.133 between (i) and (iii), Figure 3). As previously shown, the insertion of the GFP reporter construct at site 2 had no impact on RT when associated with a single autonomous replicon at site 3 on either the same or the other chromosome (Figure EV2, compare $-\Delta L + \Delta E$ values between D. and E.). Insertion of two autonomous replicons at sites 1 and 3, with (1+2+3) or without (1+3) the central GFP reporter construct, resulted in larger shift in RT over the whole of the genomic region targeted (Figure EV3A and B, $-\Delta L + \Delta E = +63.3\%$ and +70.3% for 1+2+3 insertions and $-\Delta L + \Delta E = +65.2\%$, +84.2%, +57.3%, for 1+3 insertions). A quantitative analysis revealed that the differences in RT between cell clones with one and two autonomous replicons were significant (*p*-value=0.01554 between (i) and (ii) and *p*-value=0.03571 between (ii) and (iii), Figure 3A). Overall, these results strongly suggest that two similar independent advanced replicons, 30 kb apart, can synergize to control the extent of the RT shift.

Genome-scale studies have shown that RT is strongly correlated with A/B compartments in human cells, suggesting spatial proximity of regions of similar RT within the nucleus (Ryba et al, 2010). We tested whether the large change in RT of the modified chromosome is accompanied by a change in the way the inserted origins interact with A and B compartments. This system allows us to assess how the early replicating allele (allele 1+3) interacts with A and B compartments compared to the allele with the endogenous RT (allele 2) (Figure 3B). We conducted Hi-C to assess compartment status genome wide and to measure long-range chromatin interactions for allele 1+3 and allele 2 at the same time. We first examined interactions between inserted sequences at alleles 1+3 and 2 and chromosome 1 (chr1). The profile of interactions of allele 1+3 with chr1 and allele 2 with chr1, demonstrates alternating patterns in the p-arm of chr1, whereas in the q-arm the two profiles show more overlap (Figure 3C and Appendix Figure S4A, D). Most of the loci that show preferred interactions with allele 1+3 coincide with loci located within A compartment domains (Figure 3C and Appendix Figure S4A, D). To further quantify the observed preference, we calculated average distance-corrected interactions between allele 1+3/allele 2 and regions of chr1 according to their compartment status (Figure 3D and Appendix Figure S4B, E). Averaged interactions confirm that allele 1+3 interacts more with A compartment than with B compartment both for p and q-arms of chr1, unlike allele 2 which shows smaller preference for A compartment in the q-arm, and no association with either A or B compartment in the p-arm. Our observations regarding allele 2 are in line with the WT compartment status of the mid-late insertion site, as shown by an eigenvector 1 (EV1) value near zero (see also Figure 7A below). We assessed the significance of the interaction preferences by re-calculating the average interactions of allele 1+3/allele 2 and regions of chr1 with randomly shuffled compartment status (EV1) (Figure 3D, Appendix Figure S4 B, E) (see Methods for details). We further looked if allele 1+3 and allele 2 demonstrated any preferential interactions with other chromosomes in the genome, by comparing their density of interactions (averaged interactions normalized by chromosome length, see Methods for details). The number of interactions with chr9 is disproportionately higher for allele 1+3 than for allele 2 compared to other chromosomes (Figure 3E, Appendix Figure S4 C, F) showing that allele 1+3 interacts more with chr9. Our results show that allele1+3 interacts more with specific A compartments located on chr1 and globally more with chr9. These specific interactions coincide with several strong replication origins and high gene density for chr9, however precise mechanistic understanding will require further investigation.

The constitutive β -actin promoter/origin is required for the synergic action of the two replicons separated by 30 kb

We have already shown that the large autonomous replicon used in this study is composed of two strong origins associated either with an active (β -actin) or an inactive (β ^A-globin) promoter (Hassan-Zadeh et al, 2012 and Appendix Figure S2 and Figure EV4A). MNase (micrococcal nuclease) titration analyses confirmed a differential chromosomal accessibility of the two minimal modules inserted separately at site 1 (Figure EV4B and C and Appendix Figure S5). However, both minimal modules individually can induce a significant RT shift (Figure 1). To understand in more details the mechanisms involved in the synergy observed in the large β ^A-globin+ β -actin construct, we tested for each minimal construct the effect of a double insertion at sites 1 and 3 on the same chromosome. We observed that similarly to the large autonomous replicon, the β -actin promoter induced a stronger shift in RT when inserted at 1+3 positions (Figure 4A and Figure EV3C). By contrast, two inactive β ^A-globin promoters did not produce any advanced RT when inserted at 1+3 sites (Figure 4B and Figure EV5). We observed for a subset of clones even a decrease in the intensity of the RT after the second insertion, a reproducible observation that cannot be explained yet. However, this last result showed that the minimal replicon containing an inactive promoter

is not able to synergize when located at two remoted positions. Moreover, it showed that the synergy observed with constructs containing the active β -actin promoter (small or large modules) did not result from the simple two-fold increase in the number of active origins in the analysed region. This result suggests that an unknown specific mechanism allowed two strong origins associated with an active TSS and separated by 30 kb to advance their RT.

The formation of the early-replicating domain is associated with the spatial proximity of the two advanced replicons

We tested the hypothesis whether the synergy between the two advanced replicons leading to the formation of an early-replicating domain involved spatial proximity between the replicons concerned. 3C experiments, after crosslinking, digestion, ligation and PCR with loci specific primers, measure the frequency of interactions between any two genomic loci. We thus could have used 3C to assess the interactions between the two advanced replicons. However, there are limitations inherent to our system: First, allele 1+3 and allele 2 share common sequences. There are two insertion sites on allele 1+3 and only one insertion site on allele 2 (Figure 3B). Therefore, we can only quantify the interactions within allele 1+3 (i.e. interactions between the two early replicons) without controls for allele 2. Second, the two early replicons located on allele 1+3 have almost similar sequences resulting in only few primers that would be 3C compatible. Third, 4C experiments could be another possibility but normalization is not trivial and interpretation of the data can be challenging in this case of different insertions on different alleles. Cre/loxP site-specific recombination has been successfully used in yeast and bacteria to assess the relative probabilities of different regions of the genome colliding with each another (Burgess & Kleckner, 1999; Hildebrandt & Cozzarelli, 1995). Since Cre/loxP sites are inside our constructs, we used this elegant Cre/loxP system instead of 3C to evaluate the spatial proximity between the two autonomous replicons located 30 kb apart. We assessed the capacity of the 5' recombination element located in the β^A -globin+ β -actin construct at site 3 (loxP RE, vellow triangle, Figure 5A) to recombine with the 3' recombination element in the β^A -globin+ β -actin construct at site 1 (loxP_LE, green triangle, Figure 5A). The percentage of chromosomes modified by this recombination (Figure 5C and Appendix Figure S6A, large 1+3 excision) was quantified in cell clones with 1+2+3 and 1+3 configurations, 1 h, 8 h, 24 h and 48 h after the induction of the Cre recombinase. We evaluated the frequency of random contacts by constructing new clones in which the advanced replicon inserted at site 1 was replaced by a $loxP_LE$ element alone (Figure 5A, $loxP_LE$ (1)+ β^A -globin+ β -actin (3)). We quantified the large excision product of the modified chromosome by semi-quantitative PCR on the whole cell population with a specific primer pair (Figure 5B, Up large excision and Low large excision). The percentage of cells containing this excision product increased steadily over time, from 6 to 14% after 1 h to 43% to 89% of the cells after 48 h of Cre recombinase induction (Figure 5C and Appendix Figure S6A). By contrast, only small amounts of this product were detected in three independent clones carrying the $loxP_LE(1) + \beta^{A}$ -globin+ β -actin (3) configuration, (from 3% after 1 h to 12% of the cells after 48 h of Cre recombinase induction; Figure 5C and Appendix Figure S6A). Recombination rates varied by five to eightfold between the two types of configuration, as reported for yeasts harboring different combinations of loxP sites (Burgess & Kleckner, 1999). Since the loxP_LE element is located either at the end of the actively transcribed BsR gene or alone at site 1 in the two configurations, we investigated whether the difference in recombination efficiency might be due to differences in chromatin accessibility at this position. We therefore tested the chromatin accessibility of loxP_LE at site 1 in the two configurations by assessing the MNase sensitivity (Figure 6A,B). The heterochromatin region located upstream from the early-replicating β -globin locus was used as a control for the condensed state and the transcriptionally active MED14 promoter for the open state (Litt et al, 2001; Prioleau et al, 1999). We detected similar small amounts of DNA release from loxP_LE in both configurations, for all MNAse concentrations showing that the loxP_LE element had similar accessibility in both configurations. Since two β -actin constructs can also synergize when inserted at sites 1 and 3 (Figure 4A), we tested their capacity to recombine after Cre recombinase induction. We observed a similar behavior as previously with the large β^A -globin+ β -actin construct (Figure 5C and Appendix Figure S6B). Overall, our data strongly suggest the existence of molecular contacts between the two constructs synergistically acting on RT. The formation of the early-replicating domain is, thus, linked to a spatial connection between the two advanced replicons containing an active promoter and located 30 kb apart. It suggests that the two advanced replicons might form a chromatin loop.

The close spatial proximity of the two advanced replicons is not associated with an increase in chromatin accessibility

We then investigated whether the synergy of the two autonomous replicons associated with their physical proximity affected the chromatin accessibility of these replicons or of one of the genomic regions located within the early-replicating domain. We addressed this question by quantifying, nuclease-treated chromatin in 1+2+3 and 1+3 cell lines, by qPCR with specific primer sets specifically amplifying at either one or both autonomous β^A -globin+ β -actin replicons, at the central GFP reporter transgene, at the three insertion sites or at control loci (Figure 6A,B). We compared chromatin accessibility between these cell lines and the one having only one β^A -globin+ β -actin construct inserted at site 1 (Figure EV4D.). We observed an increase in total nucleosome release at insertion site 3 relative to insertions sites 1 and 2 and condensed chromatin controls, for all MNAse concentrations. The chromatin of this insertion site is, therefore, more accessible than that at sites 1 and 2 (Figure 6, insertion site 3). The β -actin module harbors the same pattern of accessibility as observed with one autonomous replicon (compare Figure 6B. and Figure EV4C.). Nucleosomes embedded within the upstream 2xFIV element of the β^A -globin+ β -actin construct at site 3 (5' 2xFIV-3) and within the *PuroR* gene were more susceptible to MNAse, regardless of MNAse concentration, than nucleosomes embedded at similar positions (5' 2xFIV-1 and BsR gene) in the β^A -globin+ β -actin construct at site 1. The chromatin at this site is, therefore, also more exposed, probably reflecting the greater accessibility of the unmodified site 3. The GFP reporter construct in the middle of the early-replicating domain (1+2+3) or on the other mid-late-replicating unmodified chromosome (1+3), released similar small amounts of material for all MNAse concentrations as were detected for heterochromatin regions or at the unmodified site 2. We can conclude from these results that two modules composed of 5.6 kb of accessible chromatin and containing efficient replicators separated by 30 kb are sufficient to create an early-replicated domain when inserted into a naturally closed mid-late-replicating region. These two constructs can establish spatial connections without increasing the accessibility of their own chromatin, or the accessibility of the chromatin located in the middle of the early-replicating domain.

Two late-replicating environments embedded into a B compartment are permissive to a shift towards earlier replication after the site-specific insertion of a large autonomous replicon

It remains unknown whether late-replicating regions are permissive to early timing control elements. One hypothesis is that the nuclear and chromatin organizations of late-replicating domains impose robust constraints that prevent earlier firing. We addressed this question directly, by investigating whether the β^A -globin+ β -actin construct behaves as efficiently when targeted to regions naturally displaying very late replication and located in a B compartment. We selected two late-replicating regions from the genome-wide RT profile obtained for wt DT40 cells. One of these regions was located 2 Mb upstream from the previously studied mid-late-replicating region on chromosome 1 (Late1 chr1:70,523,649 and mid-late chr1:72,565,520 bp, galGal5; Figure 7A) and the other was located 105.4 Mb downstream from this mid-late-replicating region (Late2 chr1:177,936,192 bp, galGal5, Figure 7B). The late 2 locus is characterized by gene depletion over a 500 kb region in contrast to the late 1 locus (Figure 7). In addition, we know from a previous study that the two late loci are found at the nuclear periphery in DT40 cells. However, the late 2 locus is more tightly associated with nuclear lamina than the late 1 (Figure 6 in (Duriez et al, 2019)). Altogether, it strongly suggests that the late 2 locus is a constitutive late domain whereas the late 1 locus might be a facultative late domain. We confirmed that these two regions were, indeed, replicated much later than the previously studied region (Figure 8A, B, Without). We calculated $-\Delta L + \Delta E$ values for cell clones containing the β^A -globin+ β actin transgene inserted into these late-replicating regions (Figure 8). We observed a strong impact on RT of transgene insertion at the late 1 site (Figure 8A). The RT shift was comparable with the one observed following insertions into the previously studied mid-late-replicating region ($-\Delta L + \Delta E = +29.3\%$ for clone 1

and +51.7% for clone 2, Figure 8A. versus smallest and greatest - Δ L+ Δ E values calculated for eight clones: +23.3% and 52.9%, respectively, in the mid-late-replicating region, Figure 1). However, in the late 2 region, we detected a slightly lower, but nevertheless significant shift in RT, than that induced in a mid-late-replicating region (- Δ L+ Δ E = +16.1% for clone 1, +19.1% for clone 2 and +21.3% for clone 3, Figure 8B). Our findings confirm the robustness of the previously identified combination of *cis*-elements to advance the RT. We show here that the β ^A-*globin*+ β -*actin* combination can impose local autonomous control over RT in at least three chromosomal regions, one replicating in mid-late S phase and the other two displaying late replication among which one is a constitutive late domain (Late 2).

Discussion

The DNA RT program has emerged as a system that integrates genome regulation and the three-dimensional organization of the genome. From these observations was proposed the replication domain model in which each RT domain acts as a regulatory unit, determining when the replications within its boundaries can fire. We challenged this model, by disturbing naturally mid-late- and late-replicating domains after site-specific insertion of constructs containing critical *cis*-elements known to regulate origin firing. Based on the work described here, we identified five important principles underlying the establishment and maintenance of domains of early and late replication: (1) A strong origin embedded into an accessible chromatin structure can significantly advance the RT of a mid-late-replicating region; (2) Two replicators carrying timing information can act in cooperation if located in close proximity; (3) Strong autonomous replicons overlapping an active promoter can act in synergy on RT even when separated by 30 kb to form early-replicated regions; (4) The formation of an early-replicating domain results locally in the formation of a spatial connection between the advanced replicons and on a larger scale in an increase of contacts with the A compartment; (5) The RT of late-replicating domains can be advanced locally by a strong autonomous replicon, but the final RT is also influenced by chromosomal context.

Molecular mechanisms shaping efficient replicons carrying timing information

Studies in S. cerevisiae have suggested that the correct temporal activation of origins during S-phase involves the activation of early-firing origins, because these origins have a greater "accessibility" to firing factors, which are present in limiting amounts. After firing, the limiting factors are released and can bind to and activate less accessible origins, and so on (Douglas & Diffley, 2012). This theory suggests that the RT of a region directly reflects the accessibility to these limiting factors of specific regions bound by pre-RCs. In vertebrate cells, there is a strong correlation between early replication and the accumulation of open chromatin marks, consistent with a role for the openness of chromatin in the recruitment of these potential limiting factors (Picard et al, 2014; Ryba et al, 2010). We previously identified a combination of ciselements constituting an independent replicon with the capacity to advance RT of a 250 kb mid-latereplicating region significantly (Hassan-Zadeh et al, 2012 and Figure 2A). This construct contains only promoters and regulatory motifs naturally present in the chicken genome (one tissue-specific promoter, one constitutive promoter and four FIVs elements), linked to either the IL2R reporter gene or the blasticidin gene selection cassette. Moreover, autonomous replicon activity is driven only by endogenously expressed trans-factors. Investigation of the chromatin structure of each independent unit revealed a number of different features, highlighting the potential diversity of *cis*-elements involved in RT control in vertebrates. One of the elements identified contains the β^A -globin erythroid tissue-specific promoter which cannot drive transcription in the DT40 lymphoid cell line. The other element contains the constitutive β -actin promoter linked to a gene for selection. This strong origin/promoter facilitates the local opening of chromatin structure and the acquisition of H3K4me3 and H3K9K27ac marks at the inserted position (Figure EV4E). These findings are consistent with the observation that the synthetic activation of transcription, but not nuclear repositioning, shifts the RT of several mid-late-replicating loci to mid-early in mouse ES cells (Therizols et al, 2014). Our first observation shows that, at least at this mid-late-replicated chromosomal position, origins located within the β^{A} -globin and β -actin promoters are highly efficient, because they were able to advance RT locally in a population-based timing assay. We were unable to estimate the fraction of cells in which these two replicators were activated, but the significant shift in RT towards earlier replication strongly suggests that they are activated in a large proportion of cells. Based on genome-wide studies and our recent genetic study, we suggest that most vertebrate origins consist of a G-quadruplex motif linked to an as yet undefined cis-element, and that replicators overlapping a promoter tend to be the most effective (Besnard et al, 2012; Cayrou et al, 2012; Valton et al, 2014). Both the β^A -globin and β -actin promoters/origins contain several G-quadruplex motifs and locally induce strong SNS enrichment when inserted ectopically, thereby satisfying the criteria for a "canonical strong origin" (Hassan-Zadeh et al., 2012 and Appendix Figure S2). Statistical analyses showed that these origins together with cis-elements controlling chromatin structure could act in cooperation when located close together by providing more effective timing information. This result supports the hypothesis that early-replicating domains result from the clustering of origins embedded within an open chromatin structure. Consistent with this hypothesis, genome-wide mapping of replication origins by the SNS method in human and mouse cells has shown the clustering of efficient replication origins within early-replicated domains, forming small initiation zones of several kilobases, mostly located around TSS containing a CpG island (CGI) (Cayrou et al, 2015; Picard et al, 2014). Our two linked RT shiftinducing constructs are thus reminiscent of the organization of the endogenous structure of early-replicated domains.

Early replicators can advance RT locally in late-replicating domains

We investigated the possible dominance of late-replicating domains over replicators carrying early timing information, by assessing the capacity of the same previously dissected combination of *cis*-elements to function as an independent replicon in genomic regions that are naturally replicated in late S-phase. This construct has the ability to advance significantly the RT at three chromosomal loci (one replicated in midlate S-phase and two in late S-phase), demonstrating the robustness of the signal embedded in this specific construct. With respect to the replication domain model, these findings suggest that any type of chromosomal environment, including a large constitutive late domain, is permissive for the formation of an

autonomous advanced replicon. However, the observation that the final RT for the modified region was more advanced for the region normally replicated in mid-late S-phase than for that normally replicated in late S-phase suggests that there may be two layers of regulation, at the local and large scales. Both these levels of regulation must be taken into account if we are to understand how large replication domains are constructed. Our data suggest that late-replicating domains are also defined by a lack of signals associated with autonomous early replicons. Consistent with this hypothesis, one mechanism proposed for the regulation of late-replicated regions associated with common fragile sites involves a low density of replication initiation events (Letessier *et al.*, 2011). Less abundant but nevertheless efficient origins can also be detected in late-replicating domains by the SNS method. A recent study investigated the role of H4K20me marks in controlling late-firing origins. It showed that the conversion of K20me1 to K20me3 enhances ORCA recruitment and MCM loading at already defined origins required for the correct replication of heterochromatin (Brustel *et al.*, 2017). Interestingly, the loss of Suv4-20h, which is responsible for this methylation, delays RT for 15% of the mouse genome. Late origins are, therefore, also defined by a specific chromatin organization facilitating the coordination of late-firing and counteracting the overall repressive effect of heterochromatic regions without providing early-firing signals.

Robust early-replicated domains can be formed by synergy between efficient early replicators separated by several tens of kilobases

We investigated the formation of early-replicating domains further, by inserting two identical strong combinations of early origins into the same chromosome, at sites 30 kb apart. This distance is within the range of average spacing between strong initiation sites or zones detected by the SNS method in early-replicated domains. To our surprise, we found that these two inserted constructs advanced RT to a much greater extent when inserted together than when inserted alone. We found that the presence of the two constructs favored physical contact between these two remote regions. We suspect that this spatial connection is required for the synergic effect on RT, although we have no definitive proof that this is the

case. Interactions between active promoters have been observed by several methods, including the recent production of an ultrahigh-resolution Hi-C map during neural differentiation in mice (Bonev et al, 2017; Li et al, 2012). Moreover, a recent study proposed that origins of replication tend to cluster even more efficiently than promoters themselves (Jodkowska et al, 2019). These results are consistent with our observations, because our construct shown to act synergically contains the constitutive β -actin promoter. In S. cerevisiae the Fkh1/2 transcription factors have been shown to be directly involved in the early-firing of a large group of origins (Knott et al, 2012). It has recently been shown that this function involves direct interaction with Dbf4, the regulatory unit of the essential DDK firing factor (Fang et al, 2017). Based on the dimerization capacity of Fkh1/2 and the observation that early-firing origins associated with Fkh1/2 tend to cluster, it was suggested that this clustering might even increase the efficiency of Fkh1/2 for the local recruitment of Dbf4 to early replication factories (Knott et al, 2012). Recently, replication initiators containing intrinsically disordered regions (IDRs) have been described in *Drosophila melanogaster* and constitute a new class of phase separating elements that undergo liquid-liquid phase separation (LLPS) upon DNA binding in vitro. These elements may drive through IDR-IDR interactions a spatial co-localization of multiple active replication origins within a nuclear zone, which could also favor a better accessibility to firing factors (Parker 2019). We thus suggest that the close proximity of two strong autonomous replicators carrying early timing information here locally increased the efficiency of limiting firing factor recruitment in a similar manner. Most efficient early-firing origins are associated with active promoters containing CGI. This model is, therefore, consistent with genome-wide observations, validating our synthetic approach.

Methods

Plasmid construction

The targeting vectors for homologous recombination in DT40 cells were constructed with the multisite Gateway Pro kit (Thermo Fischer Scientific #12537100), as previously described (Hassan-Zadeh *et al*, 2012). The same entry vectors as before were used for the 5' and 3' target arms for specific insertion at site 1 in the mid-late-replicating region (chr1:72,565,520 bp, galGal5) (Hassan-Zadeh *et al*, 2012). New arms

were prepared for specific targeting at sites 2 (chr1: 72,548,589 bp, galGal5) and 3 (chr1: 72,536,060 bp, galGal5) in the mid-late-replicating region, and at sites 1 (Late1 chr1:70,523,649 bp, galGal5) and 2 (Late2 chr1:177,936,192 bp, galGal5) in the late regions. The 5' and 3' target arms for homologous recombination were amplified from DT40 genomic DNA with the primer pairs listed in Appendix Table S3.

We used four entry vectors to generate the new β^4 -globin+ β -actin construct inserted at site 1: two entry vectors containing the 5' and 3' target arms for specific insertion at site 1 (Appendix Table S3) and two new entry vectors. The first contained two copies of FIV linked to the β^4 -globin promoter (2xFIV_ β^4 -globin). The 2XFIV_ β^4 -globin entry vector was used as a template for PCR amplification with the following primers: 2XFIV_ β^4 -globin-Up/Low (Appendix Table S3). The second entry vector (2xFIV_ β -actin+BsR) contained the 2xFIV elements upstream from the β -actin promoter linked with the blasticidin resistance gene (BsR), flanked by loxP sites. This construct was made by amplifying the β -actin promoter from the pLoxBsR vector (Arakawa et al, 2001) such that XhoI and 2xFIV sequences were added upstream from the promoter with the following primers: 2XFIV_ β -actin-Up/Low (Appendix Table S3). The PCR product was inserted into the previously described β -actin promoter and the BgIII site at the end of the promoter by ligation with T4 DNA ligase (BioLabs #M0202S), and the 2xFIV_ β -actin+BsR entry vector was selected after sequence verification. The corresponding final vector was generated by recombining compatible att sites between the entry vectors, with LR clonase. For electroporation, the final vector was linearized with ScaI (NEB #R3122S).

We used four entry vectors to generate the β^A -globin+ β -actin construct inserted at site 3. We used two entry vectors containing the 5' and 3' target arms for specific insertion at site 3 (Appendix Table S3), the previously described $2XFIV_{\beta}^A$ -globin entry vector and a new entry vector $(2xFIV_{\beta}-actin+PuroR)$ containing the 2xFIV sequence upstream from the β -actin promoter linked with the puromycin resistance (PuroR) gene, flanked by loxP sites. This construct was made by amplifying part of the entry vector from the previously described β^A -globin+ β -actin vector such that the attB sites were flanked by the XhoI restriction site and 2xFIV sequences on one side of the recombined region and the XhoI sequence on the

other, with the following primer pair: XhoI+2xFIV-Up/Low (Appendix Table S3). The β -actin promoter associated with the PuroR gene cassette was produced by XhoI digestion of the pLoxPuro plasmid (Arakawa et~al, 2001). The final $2xFIV_\beta$ -actin+PuroR entry vector for insertion at site 3 was generated by XhoI digestion of the PCR product and ligation with T4 DNA ligase. The corresponding $2xFIV_\beta$ -actin+PuroR entry vector was selected after sequence verification. The final vector was generated by recombining compatible att sites between the four entry vectors, with LR clonase. For electroporation, the final vector was linearized with PvuI (NEB #R3150S).

We used four entry vectors to generate the *GFP* reporter construct inserted at site 2. We used two entry vectors containing the 5' and 3' target arms for specific insertion at site 2 (Appendix Table S3), one entry vector previously described and containing a similar β -actin+BsR cassette flanked by two loxP sites (Hassan-Zadeh et al, 2012) and one new entry vector (β^A -GFP-h.K7). This entry vector contained the β^A -globin promoter sequence amplified from the previously described 2xFIV_ β^A -globin entry vector with the following primer pair: β^A -Up/Low, the GFP gene sequence amplified from the peGFP plasmid (Clontech #6085-1) with the following primer pair: GFP-Up/Low and part of human chromosome 7 (chr7:26,873,165-26,874,805 bp, hg38) amplified from human genomic DNA with the following primer pair: h.K7-Up/Low (Appendix Table S3). The β^A -Up and h.K7-Low primers were associated with the corresponding attB sites for Gateway recombination. These three DNA fragments were combined with the In-Fusion HD cloning plus kit (Takara #638909), introduced into the corresponding entry vector with BP clonase (Thermo Fisher Scientific #11789020) and selected after sequence verification. The final vector was generated by recombining compatible att sites between the four entry vectors, with LR clonase (Thermo Fisher Scientific #12538120). For electroporation, the final vector was linearized with PvuI (NEB #R3150S).

The $loxP_LE$ sequence was inserted into site 1 by the insertion of a larger construct composed of the $loxP_LE$ -h.K7+ β -actin+BsR elements followed by site-specific Cre recombinase excision. This construct was generated by the association of two entry vectors containing the 5' and 3' target arms for specific insertion at site 1, a previously described entry vector containing a similar β -actin+BsR selection cassette (Hassan-Zadeh *et al*, 2012) and a new entry vector ($loxP_RE$ -h.K7). This entry vector contained part of the

human chromosome 7 sequence amplified from human genomic DNA with the following primer pair containing the upstream $loxP_RE$ sequence: $loxP_RE$ -h.K7-Up/Low (Appendix Table S3). The $loxP_RE$ -h.K7-Up and the $loxP_RE$ -h.K7-Low primers were associated with the corresponding attB sites. The PCR products were introduced into the corresponding entry vector with BP clonase and selected after sequence verification. The final vector was generated by recombining compatible att sites between the four entry vectors, with LR clonase. For electroporation, the final vector was linearized with PvuII (NEB #R3151S). We used four entry vectors to generate the new β^A - $globin+\beta$ -actin construct inserted at site late 1 and late 2: two entry vectors containing the 5' and 3' target arms for specific insertion at site late 1 or late 2 (Appendix Table S3) and the previously described β^A -globin and β -actin+BsR entry vectors (Hassan-Zadeh et al, 2012). We used three entry vectors to generate the β -actin construct inserted at site 1 and 3: the previously described β -actin+BsR or β -actin+PuroR entry vector (Hassan-Zadeh et al, 2012), one entry vector containing the 3' target arm for specific insertion at site 1 or 3 and a new entry vector containing the 5' target arm for specific insertion at site 1 or 3 flanked by att sequences necessary for Gateway recombination using three entry vectors (Appendix Table S3).

Cell culture and transfection

DT40 cells were grown in RPMI 1640 Glutamax (Thermo Fisher Scientific #61870010) containing 10% FBS, 1% chicken serum, 0.1 mM β-mercaptoethanol, 200 U/mL penicillin, 200 μg/mL streptomycin and 1.75 μg/mL amphotericin B, at 37°C, under an atmosphere containing 5% CO₂. We transfected DT40 cells as previously described (Hassan-Zadeh *et al*, 2012). Cell clones were selected on media containing a final concentration of 20 μg/ml blasticidin or 1 μg/ml puromycin, depending on the resistance gene carried by the transgene. Genomic DNA was extracted from cells in lysis buffer (10 mM Tris pH8.0; 25 mM NaCl; 1 mM EDTA and 200 μg/mL proteinase K). Clones into which the plasmid DNA was integrated were screened by PCR with primer pairs designed to bind on one side of the insertion site such that one primer bound within the construct and the other primer bound just upstream or downstream from the arm used for recombination, as previously described (Hassan-Zadeh *et al*, 2012)(Appendix Figure S7 and Appendix

Table S4). The insertion of constructs into the same chromosome or the other chromosome was determined by long-range PCR (Appendix Figure S8). For each clone tested, genomic DNA was extracted with the DNeasy Blood & Tissue kit (Qiagen #69504). We designed primer pairs amplifying in the part of the genome between constructs to control for DNA extraction quality (Ctrl), and primer pairs amplifying the two tested constructs to test the insertions (Appendix Table S4). The LR 1+2 primer pair was used to amplify the h.K7 part of the GFP reporter construct inserted at site 2 and the IL2R gene within the β^A -globin+ β actin construct inserted at site 1. The LR 2+3 primer pair was used to amplify the PuroR gene within the β^{A} -globin+ β -actin construct inserted at site 3 and the GFP gene within the GFP reporter construct inserted at site 2. The LR 1+3 primer pair was used to amplify the *PuroR* gene within the β^A -globin+ β -actin construct inserted at site 3 and the IL2R gene within the β^A -globin+ β -actin construct inserted at site 1, regardless of the presence or absence of the central construct. The LR $loxP_LE(1) + \beta^A - globin + \beta - actin$ (3) primer pair was used to amplify the *PuroR* gene within the β^A -globin+ β -actin construct inserted at site 3 and the loxP_LE element inserted at site 1, regardless of the presence or absence of the central construct. PCR was performed with the Long PCR Enzyme Mix (Thermo Fisher Scientific #K0181) under following conditions: initial denaturation at 94°C for 3 minutes, followed by 10 cycles of 95°C for 20 s, 68°C for 14 minutes, followed by 20 cycles of 95°C for 20 s, 68°C for 18 minutes and a final extension phase of 10 minutes at 68°C. Quantitative PCR (qPCR) was carried out for each clone, on 4 ng of genomic DNA, with a primer binding to the transgene (With on the GFP reporter construct, With on β^A -globin+ β -actin construct, With on β -actin and loxP_LE on the loxP site inserted at site 1), and a primer binding close to insertion site 1 and amplifying both alleles (Both or insertion site 1 + 5 kb), to confirm that only one copy of the transgene had been inserted (Appendix Table S2 and S3).

Cre-loxP excision

In this study, we used the DT40 Cre1 subclone, which constitutively expresses a tightly regulated Cre recombinase fused to a mutated estrogen receptor (Mer) (Arakawa *et al*, 2001). This inactive Mer-Cre-Mer fusion protein can be transiently activated in the presence of 4-hydroxytamoxifen, resulting in the efficient

excision of genomic regions flanked by two recombination signals (loxP sites) inserted in the same direction. We also used a modified inducible Cre recombination system involving two different mutant loxP sites (loxP RE and loxP LE). After Cre recombination, these two mutants are converted into a new nonfunctional loxP site (loxP_RE+LE) that is not recognized by the Cre recombinase, thereby preventing additional recombination events (Arakawa et al., 2001). For the excision of the genomic DNA flanked by loxP sites, we treated 3 x 10⁵ cells with 5 μM 4-hydroxytamoxifen (Sigma Aldrich #T176) for two days. Subclones were obtained by plating dilutions of the treated cell suspension at a density of 50, 150, and 1500 viable cells per 10 ml in 96-well flat-bottomed microtiter plates. Genomic DNA was extracted from single subclones and analyzed by PCR with specific primer pairs (Appendix Table S4). We assessed the excision of the β -actin +BsR selection cassette in clones with the GFP reporter construct inserted at site 2, with a primer pair amplifying the polyA sequence of the both BsR and GFP genes and the downstream part of the 3' arm of insertion site 2 (Appendix Figure S7, primer pair #3-4, BsR excision site 2, Appendix Table S4). We assessed the excision of the β -actin+PuroR selection cassette in clones with the β ^A-globin+ β -actin construct inserted at site 3 and already containing the β^A -globin construct at site 1 (Hassan-Zadeh et al, 2012), with a primer pair amplifying the polyA sequence of the both IL2R and PuroR genes and the downstream part of the 3' arm of insertion site 3 (Appendix Figure S7, primer pair #5-6, PuroR excision at site 3, Appendix Table S4). All clones were cultured for 72 h in selective media containing the appropriate antibiotic, to confirm PCR results.

For the large 1+3 excision kinetic, 3×10^6 cells were treated with $5 \mu M$ 4-hydroxytamoxifen for 1, 8, 24, 48 h before genomic DNA extraction with the DNeasy Blood & Tissue kit (Qiagen #69504). The large 1+3 excision was quantified by semiquantitative PCR with the large excision primer pair and the Ctrl primer pair used for normalization (Figure 5, Appendix Figure S6 and Appendix Table S4). Calibration was based on a standard curve generated with various amounts of genomic DNA (16 ng to 160 ng) obtained from a previously isolated clone in which the large recombination had occurred. For each set of excision kinetic conditions, 64 ng or 160 ng of genomic DNA was tested (for amplification with the Ctrl or the large excision primer pair, respectively). PCR was performed with the Herculase II fusion DNA polymerase (Agilent

Technologies #600675) under the following conditions: initial denaturation at 98°C for 4 minutes, followed by 25 cycles of 98°C for 30 s, 57°C for 45 s, 72°C for 2 minutes, and a final extension phase for 3 minutes at 72°C. After migration of the PCR products on a 0.8% agarose gel and SYBR Safe staining, the mean intensity of each signal was quantified with Image J, corrected with the local background mean intensity and normalized with the mean intensity of the signal obtained in the control amplification.

RT analysis

The RT experiments presented in Figure 8, Figures EV1, EV2, EV3 and EV5 were performed as previously described (Hassan-Zadeh et al, 2012). Briefly, about 10⁷ exponentially growing cells were pulse-labeled with 5-Bromo-2'-deoxyuridine (BrdU, Sigma-Aldrich #B9285) for 1 h and sorted into four S-phase fractions, from early to late S phase. The collected cells were treated with lysis buffer (50 mM Tris pH 8.0; 10 mM EDTA pH 8.0; 300 mM NaCl; 0.5% SDS, 0.2 mg/ml of freshly added proteinase and 0.5 mg/ml of freshly added RNase A), incubated at 65°C for 2 h and stored at -20°C, in the dark. Genomic DNA was isolated from each sample by phenol-chloroform extraction and alcohol precipitation and sonicated four times for 30s each, at 30s intervals, in the high mode at 4°C in a Bioruptor water bath sonicator (Diagenode), to obtain fragments of 500 to 1000 bp in size. The sonicated DNA was denatured by incubation at 95°C for 5 minutes. We added monoclonal anti-BrdU antibody (BD Biosciences #347580) at a final concentration of 3.6 µg/ml in 1x IP buffer (10 mM Tris pH 8.0, 1 mM EDTA pH 8.0, 150 mM NaCl, 0.5% Triton X-100, and 7 mM NaOH). We used 30 µl or 50 µl of protein-G-coated magnetic beads (from Ademtech #4342 or Thermo Fisher Scientific #10004D, respectively) per sample to pull down the anti-BrdU antibody. Beads and BrdU-labeled nascent DNA were incubated for 2-3 hours at 4°C, on a rotating wheel. The beads were then washed once with 1x IP buffer, twice with wash buffer (20 mM M Tris pH 8.0, 2 mM EDTA pH 8.0, 250 mM NaCl, 0.25% Triton X-100) and then twice with 1x TE buffer pH 8.0. The DNA was eluted by incubating the beads at 37°C for 2 h in 250 µl 1x TE buffer pH 8.0, to which we added 1% SDS and 0.5 mg/ml proteinase K. DNA was purified by phenol-chloroform extraction and alcohol precipitation and resuspended in 50 µl TE.

For Repli-seq analyses, immunoprecipitated NS from the four S-phase fractions collected by flow cytometry or from an asynchronous cell population were amplified by whole-genome amplification (GenomePlex Complete Whole Genome Amplification kit #WGA2; Sigma) according to the manufacturer's recommendations to obtain sufficient DNA amount. After amplification, libraries were constructed with the NEBNext Ultra II DNA Library Prep Kit for Illumina (NEB #E7645S) following the manufacturer's instructions with minor modifications. For the adaptor ligation, undiluted adaptor and no size selection were used. The library amplification was performed using NEB-Next Multiplex Oligos for Illumina (NEB #E7710S) with nine different NEB-Next index primer and the NEB-Next Universal PCR Primer (NEB #E6861A) with three PCR cycles. Library purification was performed with the SPRI-select Reagent kit (Beckman coulter #B23317), and the final elution step was reduced to 33µl of 0.1×TE. The mean size of the library molecules determined on an Agilent Bio-analyser High Sensitivity DNA chip (Agilent technologies, #5067–4626) was 330-350 bp. Sequencing was performed on a NextSeq 500 Illumina sequencer with a High Output 150 cycles flow cell (paired-end reads of 75 bp) according to standard procedures. For each sample, 15-20 M of reads were generated. All Illumina sequencing runs were performed at the GENOM'IC facility of the Cochin Institute.

Repli-Seq data processing

Paired-end sequencing data were mapped on the galGal5 chicken genome using bowtie2 (Langmead & Salzberg, 2012). For each timing fraction, replication timing was computed using 50kb sliding windows at 10kb intervals, normalized by the global and local genomic coverage of the asynchonous cell population, to normalize for total and local coverage variations. Then the centered and standardized timing profiles were smoothed using cubic splines (smooth.spline function of R). In order to provide a single RT profile combining all fractions, we used the method proposed by (Du *et al*, 2019), by computing the weighted average WA = (0.917*G1) + (0.750*S1) + (0.583*S2) + (0.417*S3) + (0.250*S4) + (0*G2). An increase in WA indicates an earlier timing.

Flow cytometry analysis

After BrdU incorporation, DT40 cells were washed twice with PBS, fixed in 75% ethanol and stored at -20°C. On the day of sorting, fixed cells were resuspended at a final concentration of 2.5 x 10⁶ cells/mL in 0.1% IGEPAL in PBS (Sigma, #CA-630), 50 μg/ml propidium iodide and 0.5 mg/ml RNase A, and incubated for 30 minutes at room temperature. Cells were sorted with an INFLUX 500 cell sorter (Cytopeia, BD Biosciences). Four fractions of S-phase cells (S1-S4), each containing 5x10⁴ cells, were collected and further treated for locus-specific RT analyses. Two fractions of S-phase cells (S1-S2), each containing 10⁵ cells were collected and further treated for genome-wide RT analyses.

MNAse digestions

We cross-linked $30x10^6$ exponentially growing cells by incubation for 5 min with 1% (v/v) freshly prepared formaldehyde (Thermo Fisher Scientific, #28908) at room temperature. Fixation was stopped by adding glycine to a final concentration of 0.125 M and incubating for five minutes at room temperature, with stirring. Cells were then washed three times in cold PBS and their nuclei were extracted in 3 mL of lysis buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 3 mM MgCl₂, 0.2% Triton X-100, 0.5 mM EGTA pH 8.0, 1 mM DTT, 1x protease inhibitor cocktail (Sigma, #P8340)) for 5 minutes at 4°C, centrifuged and resuspended in digestion buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 3 mM MgCl₂, 1 mM CaCl₂, 1x protease inhibitor cocktail (Sigma, #P8340)). Micrococcal Nuclease (MNase; Thermo Fisher Scientific, #EN0181) digestions were performed for 15 minutes at 37°C, using either a final concentration of 10 U/mL for ChIp analyses or a series of four exponentially increasing concentrations of MNase (2.5, 10, 40 and 160 U/mL) for chromatin accessibility analyses. The reaction was stopped by adding 0.1 volumes of stop buffer (200 mM EDTA pH 8.0, 40 mM EGTA pH 8.0). For ChIp analyses, MNase digestion conditions were established so as to produce mostly mono- to hexa-nucleosome fragments of 150 bp to 1000 bp. Chromatin was then diluted by a factor of two in 2x complement buffer (40 mM Tris-HCl pH 8.0, 300 mM NaCl, 2% Triton X-100) and sonicated 20 times for 30s each, at 30s intervals in the high mode at 4°C in a Bioruptor water bath sonicator (Diagenode). For chromatin accessibility analyses, the lowest MNAse concentration generated a mixture of oligo-, di- and mono-nucleosomes, whereas the highest concentration produced mostly mono-nucleosomes (Appendix Figure S5A). After digestion, DNA molecules were extracted in phenol-chloroform and precipitated with ethanol and were then subjected to a size selection process with the SPRI-select Reagent kit (Beckman coulter #B23317) using a 0.5X ratio to remove DNA molecules of more than 1000 bp in length (Appendix Figure S5B). The MNAse titration approach can be used to determine whether nucleosome release requires low or high levels of MNAse. Low levels of MNAse release large numbers of nucleosomes in accessible regions, leading to higher levels of DNA molecules. Nucleosomes embedded in less accessible regions are less likely to be released with such low levels of MNAse. Moreover, this approach provides additional information about the accessibility of loci. Indeed, highly inaccessible or condensed regions are not sensitive to higher concentrations of MNAse, whereas the chromatin of accessible regions is rapidly digested under the same conditions.

Chromatin immunoprecipitation

Immunoprecipitation was performed overnight at 4°C, in a final volume of 200 µl of 1x IP buffer (20 mM Tris-HCl pH 8.0, 2 mM EDTA pH 8.0, 150 mM NaCl, 1% Triton-X100 and 0.1% SDS) on an amount of chromatin corresponding to 10 µg of DNA, with anti-trimethylated K4H3 (AbCam, #ab8580), anti-dimethylated K4H3 (Millipore, #07-030) or anti-acetylated K9K27H3 (Millipore, #06-599) antibodies, according to the manufacturer's recommendations. Immunocomplexes were pulled down with 50 µl of protein-G-coated magnetic beads (Thermo Fisher Scientific, Dynabeads Protein G, #10004D) per sample. Beads and immunocomplexes were incubated for two hours at 4°C, on a rotating wheel. The beads were then washed once with 1x IP buffer, twice with wash B buffer (20 mM M Tris pH 8.0, 2 mM EDTA pH 8.0, 250 mM NaCl, 0.25% Triton X-100) and then twice with 1x TE buffer pH 8.0. For the anti-trimethylated K4H3 antibody, the wash buffer contained 500 mM NaCl, and an additional washing step was performed with buffer C (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 1% sodium deoxycholate, 1% NP40, 250 mM LiCl). The DNA was eluted by incubating the beads for 2 h at 37°C with 250 µl 1x TE buffer pH 8.0, to which we added 1% SDS and 0.5 mg/ml proteinase K. Cross-linking was reversed by overnight incubation

at 65°C and samples were further treated with 10 μg of RNase A for 15 minutes at 37°C, and with 20 μg of proteinase K for 1 h at 56°C. DNA was purified by phenol-chloroform extraction, precipitated in alcohol and resuspended in 100 μ l TE.

RNA extraction and reverse transcription

Total RNA were extracted from 5x10⁶ cells with the Nucleospin RNA kit (Macherey Nagel, #740955). The integrity of the extracted RNA was assessed with an Agilent 2100 bioanalyzer (Agilent RNA 6000 Nano Kit, #5067-1511) and 20 µg of total RNA was then treated with 4 units of DNAse I (NEB, #M0303S) for 1 h at 37°C. The enzyme was inactivated by adding 5 mM EDTA and incubating the reaction mixture for 10 min at 75°C. The RNA was then purified by phenol-chloroform extraction and ethanol precipitation. Reverse transcription reactions (RT-QPCR+) were then performed with 5 µg of RNA and random hexamers (NEB, S1330S), using the Superscript III Reverse Transcriptase (Thermo Fisher Scientific, #18080093) according to the manufacturer's instructions. Negative controls (RT-QPCR-) were performed with the same procedure, but without the addition of reverse transcriptase. The comparison of RT-QPCR+ and RT-QPCR-samples was used to validate DNAseI treatment and the complete digestion of the genomic DNA in the RNA samples.

Real-time PCR quantification of DNA

The Roche Light Cycler 2.0 detection system and the Absolute Q-PCR SYBR green capillary mix (Thermo Fisher Scientific, #AB1285B) were used for the real-time PCR quantification of BrdU-labeled nascent strands (NS) or genomic DNA extracted from 4-hydroxytamoxifen-treated clonal cell lines. For all reactions, real-time PCR was performed under the following cycling conditions: initial denaturation at 95°C for 15 minutes, followed by 50 cycles of 95°C for 15 s, 60°C for 30 s, 72°C for 20 s, and fluorescence measurement. Following PCR, a thermal melting profile was used for amplicon identification.

The Roche Light Cycler 480 detection system and the Light Cycler 480 SYBR Green I Master mix (Roche Applied Science, # 04707516001) were used for the real-time PCR quantification of ChIp DNA, MNAse-

digested DNA and cDNA. For all reactions, real-time PCR was performed under the following cycling conditions: initial denaturation at 95°C for 5 minutes, followed by 50 cycles of 95°C for 10 s, 61°C for 20 s, 72°C for 20 s and fluorescence measurement. Following PCR, a thermal melting profile was used for amplicon identification.

For both quantification methods, standard curves were generated from four-fold dilutions of the corresponding genomic DNA. Serial dilutions of plasmids containing the loci of interest were used as standards for cDNA quantification. Each reaction was performed at least in duplicate. The second-derivative maximum method was used to quantify sequences, as described in the Light Cycler Software.

For BrdU-labeled NS quantification, we used primer pairs binding to mitochondrial DNA to normalize enrichment in each S-phase fraction (Mitochondrial DNA), an early-replicated region (Early timing control) for the control of cell sorting, a genomic position located 5 kb downstream from insertion site 2 (Both), amplifying both alleles, for the control of accurate qPCR measurements and the studied regions in the transgenes. Specific primer pairs amplifying in the transgene (With) or the site of insertion in the wt allele (Without) were used (Appendix Table S4). In the case of clones with one or two autonomous replicons associated with the GFP reporter construct inserted on the other chromosome, we used a primer pair amplifying the GFP reporter construct to quantify the wt chromosome (Without on GFP reporter at site 2, Appendix Table S4) and a primer pair amplifying insertion site 2 to quantify the modified shifting chromosome (With at insertion site 2, Appendix Table S4).

Based on both the one-hour BrdU pulse labeling used and the mean rate of fork progression, estimated at 1.5 kb/min in DT40 cells (Maya-Mendoza *et al*, 2007), the resolution of our RT experiments cannot exceed a 90 kb window. Thus, for the analysis of RT within our 30 kb genomic region targeted with one, two or three constructs, we systematically used the With and Without primer pairs in central position 2. For the quantitative analyses, we analyzed independent clones. In Figure 1, N=10 for (i) from Hassan-Zadeh *et al*, 2012 and Valton et al., 2014, N=8 for (ii) from Hassan-Zadeh *et al*, 2012, Valton et al. 2014 and , N=7 for (iii) from Hassan-Zadeh *et al*, 2012 and this article Figure EV1A and N=8 for (iv) from Hassan-Zadeh *et al*, 2012 and this article, Figure EV1B. In Figure 3, N=8 for (i) the same clones as (iv) in Figure 1, N=5 for

(ii) from Figure EV3A and B, N=3 for (iii) from this article Figure EV2 D and E. For statistical analysis, the outliers values detected with the R outliers package were excluded from the analysis (clone 4 in Figure EV1A).

For ChIp DNA and MNAse-digested DNA quantifications, we used primer pairs amplifying the wt allele at insertion sites 1, 2 and 3 (Wt allele insertion site 1, 2 or 3), the condensed region of the endogenous β -globin locus, as a control for the heterochromatin state (cond 1 and 2), the *BU1A* promoter (*BU1A* pro) or the *MED14* promoter (*MED14* pro), as a control for the active chromatin state, at a genomic position located 5 kb downstream from insertion site 1 (1 +5 kb), amplifying both alleles and the inserted transgenes, at the positions studied (Figure 6, Figure EV4 and Appendix Table S4).

For the quantification of MNAse-digested DNA, data are presented as total chromatin input relative to condensed genomic regions (cond1 and cond2). For each clonal cell line, the mean values obtained for the two condensed genomic regions for each digestion were arbitrarily set to 1 and used to normalize independent clones for each transgenic line separately and between all transgenic lines.

For ChIp DNA quantifications, data are presented as Ip/Input signal relative to the signal for the BU1A promoter (BU1A pro) used for normalization between transgenic lines.

For cDNA quantification, we used primer pairs amplifying the second exon of the *BU1A* gene as a control for transcribed genes, the junction of exons 3-4 of the *MED14* gene and the inserted transgenes, at the studied positions (Figure EV4 and Appendix Table S4).

Hi-C methods

Hi-C was performed as described previously (Belaghzal et al., 2017) with some minor modifications. Briefly, 10 million formaldehyde cross-linked cells (1% formaldehyde for the wild types and 2% formaldehyde for the clones) were lysed and digested overnight at 37°C with 400 units of *DpnII* (NEB). Next, the DNA ends were marked with biotin-14-dATP (Thermo Fisher Scientific #19524016) for 4 hours at 23°C and ligated for 4 hours at 16°C. To remove proteins and reverse crosslink, DNA was treated with proteinase K overnight at 65°C. DNA was then purified using phenol:chloroform and biotin was removed

from unligated ends. Ligation products were fragmented by sonication to an average size of 200bp and size selected with Ampure XP beads (Beckman Coulter, # A63880) to fragments ranging from 100 to 350 bp. End repair was performed on the DNA fragments to obtain blunt ends and biotinylated ligation products were purified using streptavidin beads (Thermo Fisher Scientific #65001). dA-tailing was then performed and the TrueSeq DNA LT kits Set A (Illumina, #15041757) was used for adapter ligation and PCR amplification. PCR primers were removed using Ampure XP beads. The libraries were sequenced using 50 bp paired end reads on Illumina HiSeq4000.

Hi-C data processing

Hi-C libraries were processed using the distiller pipeline (https://github.com/mirnylab/distiller-nf). Briefly, reads were mapped to the chicken reference assembly galGal5 using bwa mem to map fastq pairs in a singleside fashion (-SP). The specific sequences of each inserted construct (allele 1+3 and allele 2) were pooled together and placed in the original galGal5 fasta file as two additional chromosomes to be able to map and balance them in the following procedure. Alignments were parsed and pairs were classified using the pairtools package (https://github.com/mirnylab/pairtools) to generate pairs files. Uniquely mapped pairs were kept and duplicated pairs arising from PCR were removed. Pairs with high mapping quality scores on both sides (MAPQ > 30) were kept and aggregated into contact matrices in the cooler format using the cooler package (Abdennur & Mirny, 2020). Data was binned and stored into multiresolution cooler files (1kb, 2kb, 5kb, 10kb, 25kb, 50kb, 100kb, 250kb, 500kb, 1Mb). All contact matrices were normalized using the iterative correction normalization (Imakaev et al, 2012) after ignoring the first 2 diagonals to avoid shortrange ligation artifacts at a given resolution. Low-coverage bins were excluded using the MADmax (maximum allowed median absolute deviation) filter on genomic coverage, described in (Schwarzer et al, 2017), using the default parameters. WT replicate 1 has 82,394,530 mapped reads with 37% cis interactions, WT replicate 2 has 139,022,250 mapped reads with 29% cis interactions, clone 4 has 541 023 662 mapped reads with 79.3% cis interactions, clone 5 has 542 918 613 mapped reads with 78.5% cis interactions (Appendix Table S5).

Additional filtering of Hi-C interactions

For all of the quantification analyses it is important to ignore the following regions: 1) large translocation on the p-arm of chr1 chr1:9,000,000-9,500,000 (Appendix Figure S9 A,B) 2) smaller translocation on the p-arm of chr1 chr1:32,270,000-32,770,000 (Appendix Figure S9 A,B) 3) beta-A globin promoter region that is included in the allele 1+3 and allele 2 inserts chr1:194,569,000-194,572,000 (Appendix Figure S9 C)) beta-actin promoter region that is included in the allele 1+3 insert chr14:4,194,000-4,197,000. Regions 3) and 4) were removed because we cannot properly assign the interactions that involved $\beta^A globin$ or $\beta^A globin$ or $\beta^A globin$ or $\beta^A globin$ or $\beta^A globin$ or the endogenous loci.

A/B compartments

A and B compartments were assigned using an eigenvector decomposition procedure (Imakaev et al, 2012) implemented in the cooltools package (https://github.com/mirnylab/cooltools, http://doi.org/10.5281/zenodo.3553140). Eigenvector decomposition was performed on observed-over-expected cis contact matrices binned at 250 kb on each library and at 100kb on the pooled libraries for a better resolution of compartments. The first eigenvectors (EV1) positively correlated with gene density were used to assign A and B compartment status to each bin. EV1 calculated at 100kb was used for all quantitative analyses that involved compartment status, if not stated otherwise.

Hi-C Allele specific analysis

In order to quantify preferential interactions of allele 1+3 and allele 2 with A and B compartments we performed the following:

(1) We corrected for distance decay as the alleles were mapped as independent chromosomes (see above) but the insertion site is located on chr1. Thus, we divided the frequency of interactions of alleles 1+3/2

with chromosome 1 by the expected value for each bin based on genomic distance from the insertion site.

(2) We calculated the average interaction of allele 1+3/2 with compartment A and B on chr1 p and q-arms,

where compartment status A was assigned if eigenvector 1 value > 0 and compartment status B if

eigenvector 1 value < 0. (3) To test the significance of observed interaction preference, we randomly

shuffled the A and B compartment status 1,000 times and calculated the difference between average

interactions of a given allele with compartment A and compartment B 'difference allele 1+3 / 2 A – B' for

every iteration. We then calculated the p-value for the observed value of 'difference allele 1+3/2 A - B'.

In order to test if allele 1+3 and allele 2 demonstrate any preferential interactions with other chromosomes,

i.e. trans-interactions, we performed the following:

(1) Due to the sparsity and lack of distance decay for trans-data, we averaged interactions on the scale of

individual chromosomes and normalized them by corresponding chromosome lengths; we refer to this

measure as density of interactions. (2) We compared the density of interactions between allele 1+3 and allele

2 with chromosomes larger than 5,000,000 bp (Figure 3E and Appendix Figure S4 C,F and Appendix Figure

S9D).

Code is available on github: https://github.com/dekkerlab/allelic-rt-supplement.git

Data availability

The deposited **GEO** database datasets produced in this study have been in the

(https://www.ncbi.nlm.nih.gov/geo/) with the accession number GSE153566.

Acknowledgments

The authors thank the members of the laboratory of M-N.P for useful insights and discussions. We thank

G.Felsenfeld and R.Veitia for critical reading of the manuscript. We thank J-F Bercher for his help in

defining the most accurate quantitative method for measuring RT shifts. We thank Griselda Wentzinger and

Magali Fradet for performing cell sorting at ImagoSeine Institut Jacques Monod platform. Sequencing of

31

replication timing data was performed by the GENOM'IC core facility at Institut Cochin-Paris. We thank Ankita Nand for doing the initial mapping of the Hi-C data. This work was supported by grants from the Association pour la Recherche sur le Cancer (Equipe Labellisée) and the Agence Nationale pour la Recherche (ANR-15-CE12-0004-01), and from the National Human Genome Research Institute (HG003143 to JD). M-N.P and B.D are supported by Inserm. JD is an investigator of the Howard Hughes Medical Institute.

Author Contributions

CB, BD and M-NP planned and supervised the project. FP performed bioinformatic analysis of the repliseq data, ALV, SV and JD conceived the Hi-C experiments, ALV conducted the Hi-C experiments. ALV and SV performed bioinformatic analysis of the Hi-C data. For all other experiments CB and M-NP designed the methodology, CB, SC, AC, ML, CG conducted the experiments, CB, BD and MN-P analyzed and validate the data, CB provided visualization of the data. CB and M-NP wrote the manuscript with input from FP, ALV and SV.

Conflict of Interests

The authors declare no conflict of interests.

References

- Abdennur N & Mirny LA (2020) Cooler: scalable storage for Hi-C data and other genomically labeled arrays. *Bioinformatics* **36:** 311–316
- Arakawa H, Lodygin D & Buerstedde JM (2001) Mutant loxP vectors for selectable marker recycle and conditional knock-outs. *BMC Biotechnol.* **1:** 7
- Besnard E, Babled A, Lapasset L, Milhavet O, Parrinello H, Dantec C, Marin J-M & Lemaitre J-M (2012) Unraveling cell type-specific and reprogrammable human replication origin signatures associated with G-quadruplex consensus motifs. *Nat. Struct. Mol. Biol.* **19:** 837–844
- Bonev B, Mendelson Cohen N, Szabo Q, Fritsch L, Papadopoulos GL, Lubling Y, Xu X, Lv X, Hugnot J-P, Tanay A & Cavalli G (2017) Multiscale 3D Genome Rewiring during Mouse Neural Development. *Cell* **171:** 557-572.e24

- Brustel J, Kirstein N, Izard F, Grimaud C, Prorok P, Cayrou C, Schotta G, Abdelsamie AF, Déjardin J, Méchali M, Baldacci G, Sardet C, Cadoret J-C, Schepers A & Julien E (2017) Histone H4K20 trimethylation at late-firing origins ensures timely heterochromatin replication. *EMBO J.* **36:** 2726–2741
- Burgess SM & Kleckner N (1999) Collisions between yeast chromosomal loci in vivo are governed by three layers of organization. *Genes Dev.* **13:** 1871–1883
- Cayrou C, Ballester B, Peiffer I, Fenouil R, Coulombe P, Andrau J-C, van Helden J & Méchali M (2015) The chromatin environment shapes DNA replication origin organization and defines origin classes. *Genome Res.* **25:** 1873–1885
- Cayrou C, Coulombe P, Puy A, Rialle S, Kaplan N, Segal E & Méchali M (2012) New insights into replication origin characteristics in metazoans. *Cell Cycle* **11:** 658–667
- Cornacchia D, Dileep V, Quivy J-P, Foti R, Tili F, Santarella-Mellwig R, Antony C, Almouzni G, Gilbert DM & Buonomo SBC (2012) Mouse Rif1 is a key regulator of the replication-timing programme in mammalian cells. *EMBO J.* **31:** 3678–3690
- Douglas ME & Diffley JFX (2012) Replication timing: the early bird catches the worm. *Curr. Biol.* **22:** R81-82
- Du Q, Bert SA, Armstrong NJ, Caldon CE, Song JZ, Nair SS, Gould CM, Luu P-L, Peters T, Khoury A, Qu W, Zotenko E, Stirzaker C & Clark SJ (2019) Replication timing and epigenome remodelling are associated with the nature of chromosomal rearrangements in cancer. *Nat Commun* **10**: 1–15
- Duriez B, Chilaka S, Bercher J-F, Hercul E & Prioleau M-N (2019) Replication dynamics of individual loci in single living cells reveal changes in the degree of replication stochasticity through S phase. *Nucleic Acids Res.* **47:** 5155–5169
- Fang D, Lengronne A, Shi D, Forey R, Skrzypczak M, Ginalski K, Yan C, Wang X, Cao Q, Pasero P & Lou H (2017) Dbf4 recruitment by forkhead transcription factors defines an upstream rate-limiting step in determining origin firing timing. *Genes Dev.* **31:** 2405–2415
- Foti R, Gnan S, Cornacchia D, Dileep V, Bulut-Karslioglu A, Diehl S, Buness A, Klein FA, Huber W, Johnstone E, Loos R, Bertone P, Gilbert DM, Manke T, Jenuwein T & Buonomo SCB (2016) Nuclear Architecture Organized by Rif1 Underpins the Replication-Timing Program. *Molecular Cell* **61:** 260–273
- Hassan-Zadeh V, Chilaka S, Cadoret J-C, Ma MK-W, Boggetto N, West AG & Prioleau M-N (2012) USF binding sequences from the HS4 insulator element impose early replication timing on a vertebrate replicator. *PLoS Biol.* **10:** e1001277
- Hildebrandt ER & Cozzarelli NR (1995) Comparison of recombination in vitro and in E. coli cells: measure of the effective concentration of DNA in vivo. *Cell* **81:** 331–340
- Hiraga S-I, Alvino GM, Chang F, Lian H-Y, Sridhar A, Kubota T, Brewer BJ, Weinreich M, Raghuraman MK & Donaldson AD (2014) Rif1 controls DNA replication by directing Protein Phosphatase 1 to reverse Cdc7-mediated phosphorylation of the MCM complex. *Genes Dev.* **28:** 372–383

- Imakaev M, Fudenberg G, McCord RP, Naumova N, Goloborodko A, Lajoie BR, Dekker J & Mirny LA (2012) Iterative correction of Hi-C data reveals hallmarks of chromosome organization. *Nat. Methods* **9:** 999–1003
- Jodkowska K, Pancaldi V, Almeida R, Rigau M, Graña-Castro O, Fernández-Justel JM, Rodríguez-Acebes S, Rubio-Camarillo M, Pau ECS, Pisano D, Al-Shahrour F, Valencia A, Gómez M & Méndez J (2019) Three-dimensional connectivity and chromatin environment mediate the activation efficiency of mammalian DNA replication origins. *bioRxiv*: 644971
- Knott SRV, Peace JM, Ostrow AZ, Gan Y, Rex AE, Viggiani CJ, Tavaré S & Aparicio OM (2012) Forkhead transcription factors establish origin timing and long-range clustering in S. cerevisiae. *Cell* **148:** 99–111
- Langmead B & Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. Nat Methods 9: 357–359
- Letessier A, Millot GA, Koundrioukoff S, Lachagès A-M, Vogt N, Hansen RS, Malfoy B, Brison O & Debatisse M (2011) Cell-type-specific replication initiation programs set fragility of the FRA3B fragile site. *Nature* **470:** 120–123
- Li G, Ruan X, Auerbach RK, Sandhu KS, Zheng M, Wang P, Poh HM, Goh Y, Lim J, Zhang J, Sim HS, Peh SQ, Mulawadi FH, Ong CT, Orlov YL, Hong S, Zhang Z, Landt S, Raha D, Euskirchen G, et al (2012) Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. *Cell* **148:** 84–98
- Lieberman-Aiden E, van Berkum NL, Williams L, Imakaev M, Ragoczy T, Telling A, Amit I, Lajoie BR, Sabo PJ, Dorschner MO, Sandstrom R, Bernstein B, Bender MA, Groudine M, Gnirke A, Stamatoyannopoulos J, Mirny LA, Lander ES & Dekker J (2009) Comprehensive mapping of long-range interactions reveals folding principles of the human genome. *Science* **326**: 289–293
- Litt MD, Simpson M, Recillas-Targa F, Prioleau MN & Felsenfeld G (2001) Transitions in histone acetylation reveal boundaries of three separately regulated neighboring loci. *EMBO J.* **20:** 2224–2235
- Massip F, Laurent M, Brossas C, Fernández-Justel JM, Gómez M, Prioleau M-N, Duret L & Picard F (2019) Evolution of replication origins in vertebrate genomes: rapid turnover despite selective constraints. *Nucleic Acids Res.* **47:** 5114–5125
- Maya-Mendoza A, Petermann E, Gillespie DAF, Caldecott KW & Jackson DA (2007) Chk1 regulates the density of active replication origins during the vertebrate S phase. *EMBO J.* **26:** 2719–2731
- Picard F, Cadoret J-C, Audit B, Arneodo A, Alberti A, Battail C, Duret L & Prioleau M-N (2014) The Spatiotemporal Program of DNA Replication Is Associated with Specific Combinations of Chromatin Marks in Human Cells. *PLoS Genet* **10**: e1004282
- Prioleau M-N & MacAlpine DM (2016) DNA replication origins-where do we begin? *Genes Dev.* **30:** 1683–1697
- Prioleau MN, Nony P, Simpson M & Felsenfeld G (1999) An insulator element and condensed chromatin region separate the chicken beta-globin locus from an independently regulated erythroid-specific folate receptor gene. *EMBO J.* **18:** 4035–4048

- Ryba T, Hiratani I, Lu J, Itoh M, Kulik M, Zhang J, Schulz TC, Robins AJ, Dalton S & Gilbert DM (2010a) Evolutionarily conserved replication timing profiles predict long-range chromatin interactions and distinguish closely related cell types. *Genome Res.* **20:** 761–770
- Ryba T, Hiratani I, Lu J, Itoh M, Kulik M, Zhang J, Schulz TC, Robins AJ, Dalton S & Gilbert DM (2010b) Evolutionarily conserved replication timing profiles predict long-range chromatin interactions and distinguish closely related cell types. *Genome Res.* 20: 761–770
- Schwarzer W, Abdennur N, Goloborodko A, Pekowska A, Fudenberg G, Loe-Mie Y, Fonseca NA, Huber W, Haering CH, Mirny L & Spitz F (2017) Two independent modes of chromatin organization revealed by cohesin removal. *Nature* **551:** 51–56
- Sima J, Chakraborty A, Dileep V, Michalski M, Klein KN, Holcomb NP, Turner JL, Paulsen MT, Rivera-Mulia JC, Trevilla-Garcia C, Bartlett DA, Zhao PA, Washburn BK, Nora EP, Kraft K, Mundlos S, Bruneau BG, Ljungman M, Fraser P, Ay F, et al (2019) Identifying cis Elements for Spatiotemporal Control of Mammalian DNA Replication. *Cell* **176:** 816-830.e18
- Therizols P, Illingworth RS, Courilleau C, Boyle S, Wood AJ & Bickmore WA (2014) Chromatin decondensation is sufficient to alter nuclear organization in embryonic stem cells. *Science* **346**: 1238–1242
- Valton A-L, Hassan-Zadeh V, Lema I, Boggetto N, Alberti P, Saintomé C, Riou J-F & Prioleau M-N (2014) G4 motifs affect origin positioning and efficiency in two vertebrate replicators. *EMBO J*.
- West AG, Huang S, Gaszner M, Litt MD & Felsenfeld G (2004) Recruitment of histone modifications by USF proteins at a vertebrate barrier element. *Mol. Cell* **16:** 453–463
- Yamazaki S, Ishii A, Kanoh Y, Oda M, Nishito Y & Masai H (2012) Rif1 regulates the replication timing domains on the human genome. *EMBO J.* **31:** 3667–3677

Figure Legends

Figure 1. Quantitative analysis of RT shifts reveals cooperation between two combinations of *cis*-regulatory elements.

Distribution of RT shifts calculated with the $-\Delta L + \Delta E$ method described in Appendix Figure S1. Different transgenes in a mid-late-replicating region are compared: the *IL2R* reporter gene under the control of the β^A -globin promoter (β^A pro) containing an inactive (i, N=10) or an active origin (ii, N=8) flanked by two copies of FIV(2xFIV), the *blasticidin* resistance gene (*BsR*) under the control of the β -actin promoter (β -act pro) (iii, N=7) or a combination of these two transgenes (iv, N=8). Data information: Blue and black triangles represent reactive *loxP* sites and recombined inactive *loxP* sites respectively. Rectangle edges correspond

to the 0.25 and 0.75 quartiles, the thick black lines represent the median, the white triangles represent the mean and the whiskers extend to the smallest and largest - Δ L+ Δ E values. Statistical analysis was performed with Wilcoxon nonparametric two-tailed tests (ns, not significant; **p<0.01; ***p<0.001).

Figure 2. One autonomous replicon inserted in the mid-late region perturbs the RT over a 250 kb region through cooperation with an endogenous strong origin

A. UCSC genome browser visualization of the mid-late insertion site of chromosome 1 (genomic positions: chr1:71,000,000-74,100,000 bp, 3.1 Mb; galGal5). RT weighted average (WA) values for the wt and the β^A -globin+ β -actin cell lines are shown. Early-replicated regions (E) are represented in orange and late replicating regions (L) in blue. Annotated genes (Ref Seq genes) are represented below. The mid-late insertion site is indicated with a red arrow and dotted line.

B. UCSC genome browser visualization of the mid-late insertion site of chromosome 1 (genomic positions: chr1:72,450,000-72,650,000 bp; 200 kb; galGal5). Tracks of nascent strands (NS) enrichments in the four S phase fractions were represented separately (S1 to S4) for the wt and the $2x(\beta^A-globin+\beta-actin)$ cell lines. NS enriched and depleted regions for each fraction are represented in purple and blue respectively. Single reads form SNS aligned and track of replication origins (Ori peaks) determined in (Massip *et al*, 2019) are reported in between. The three mid-late insertion sites 1, 2 and 3 are indicated with red arrows. Annotated genes and CpG Islands are shown below. Initiation zones (IZ) and termination zones (TZ) are reported.

Figure 3. Two advanced replicons separated by 30 kb cooperate to form a synthetic early-replicated region that is more associated with A compartments

A. Distribution of $-\Delta L + \Delta E$ values for clonal cell lines containing one advanced replicon (β^A -globin+ β -actin) inserted at site 1 (i, N=8) or 3 (iii, N=3) or at both sites on the same chromosome with one *GFP* reporter construct composed of the *GFP* reporter gene under the control of the β^A -globin promoter/origin linked to a 1.6 kb fragment of human chromosome 7 (h.K7) inserted at site 2, either on the same chromosome as 1 and 3 (1+2+3), or on the other chromosome (1+3) (ii, N=5). Data information: Blue and black triangles represent

reactive loxP sites and recombined inactive loxP sites respectively. Black vertical bars represent insertion sites. Rectangle edges correspond to the 0.25 and 0.75 quartiles, the thick black lines represent the median, the white triangles represent the mean and the whiskers extend to the smallest and largest - Δ L+ Δ E values. Statistical analysis was performed with Wilcoxon nonparametric two-tailed tests (**p<0.01).

B. Schematic representation of alleles 1+3 and 2. Data information: Blue and black triangles represent reactive *loxP* sites and recombined inactive *loxP* sites respectively. Black vertical bars represent insertion sites.

C. Interaction profiles of allele 1+3/2 with chr1 for combined Hi-C libraries: distance-corrected interactions, *i.e.* observed/expected (OE), binned at 500 kb with corresponding compartment (EV1) tracks. Red arrows represent the loci that show preferred interactions with allele 1+3 and that coincide with A compartment.

D. OE interactions of allele 1+3 (orange rectangles) and allele 2 (blue rectangles) averaged over A and B compartments for p and q-arms at 100kb bin size. A random compartment status permutation test was made and then we calculated the one-sided p-value for the observed value of 'difference allele 1+3 / 2 A - B'. Values corresponding to OE interactions of allele 1+3 and allele 2 averaged over shuffled A (red circles, N=1000) and B compartments (blue circles, N=1000) for p and q-arms. ns, not significant; **p<0.01;***p<0.001.

E. Scatterplot of density of interactions between allele 1+3 and allele 2 with chromosomes larger than 5,000,000 bp.

Figure 4. The constitutive β -actin promoter/origin is necessary for the formation of the early-replicating domain

A. Distribution of - Δ L+ Δ E values for clonal cell lines containing one β -actin construct at site 1 (i, N=7) or at site 1 and 3 (ii, N=5), on the same chromosome.

B. Distribution of - Δ L+ Δ E values for clonal cell lines containing one β^{A} -globin construct at site 1 (i, N=8) or at site 1 and 3 (ii, N=6), on the same chromosome.

Data information: (A,B) Data information: Blue and black triangles represent reactive loxP sites and recombined inactive loxP sites respectively. Black vertical bars represent insertion sites.

Rectangle edges correspond to the 0.25 and 0.75 quartiles, the thick black lines represent the median, the white triangles represent the mean and the whiskers extend to the smallest and largest $-\Delta L + \Delta E$ values. Statistical analysis was performed with Wilcoxon nonparametric two-tailed tests (**p<0.01).

Figure 5. The formation of the early-replicating domain is associated with the establishment of local interactions between the two advanced replicons separated by 30 kb

A. Clones 1+2+3, 1+3 and β -actin (1+3) described in Figure 3, together with control clones containing one β^A -globin+ β -actin construct at site 3 and one $loxP_LE$ sequence inserted at site 1 on the same chromosome with the GFP reporter construct inserted at site 2 on the other chromosome $loxP_LE$ (1)+ β^A -globin+ β -actin (3) were tested for their capacity to recombine after induction of the Cre recombinase. Yellow and green triangles represent reactive $loxP_RE$ and $loxP_LE$ sites, respectively, and black triangles represent recombined inactive loxP sites. Black vertical bars represent insertion sites.

B. Recombination between the upstream $loxP_RE$ element (yellow triangle) inserted at site 3 and the downstream $loxP_LE$ element (green triangle) inserted at site 1 leads to a large 1+3 and $loxP_LE$ (1) + β^A - $globin+\beta$ -actin (3) or β -actin (1+3) excision product.

C. After 1, 8, 24 and 48 h of 4-hydroxytamoxifen treatment, genomic DNA was extracted and quantified by semi-quantitative PCR (see Appendix Figure S6). Error bars correspond to the standard deviation for PCR duplicates. The percentages of cells with the large 1+3 and $loxP_LE(1) + \beta^A$ -globin+ β -actin (3) or β -actin (1+3) excision at each time point are shown for different cell lines.

Figure 6. The close proximity of the two advanced replicons is not associated with an increase in chromatin accessibility.

A, B. Clones 1+2+3, 1+3 (A) and $loxP_LE$ (1) $+\beta^A$ -globin+ β -actin (3) (B) were used to assess chromatin accessibility within the transgenes. The positions of the amplicons used for quantification in each shifting construct individually (thick black lines; 5' 2xFIV-1 or -3, β -actin pro-1 or -3, BsR gene, PuroR gene, LoxP site), in both shifting constructs (β^A pro 1 and 2, IL2R gene, 3' 2xFIV1-3) or in the GFP reporter construct (β^A -GFP, GFP gene, h.K7) are shown. The insertion sites on the wt chromosome (insertion sites 1, 2 and 3) and a genomic region located 5 kb downstream from the insertion site (insertion site +5kb) were used as controls for the targeted genomic region. The endogenous active MED14 promoter was analyzed as a control. Data information: (A, B) Blue and black triangles represent reactive loxP sites and recombined inactive loxP sites respectively. Black vertical bars represent insertion sites.

Quantifications by real-time qPCR of total chromatin (input) extracted from two 1+2+3, 1+3 and $loxP_LE$ $(1)+\beta^A$ -globin+ β -actin (3) clonal cell lines, after digestion with micrococcal nuclease (MNAse, 2.5 U, 10 U, 40 U, 160 U/mL) and size selection were shown. Error bars indicate the standard deviation for qPCR triplicates, for two independent clones. Data are presented as total chromatin input relative to the condensed genomic regions (cond1 and cond2) used for the normalization.

Figure 7. Genome wide overview of genomic features at the targeted insertion sites in DT40.

A, B. UCSC genome browser visualization of two parts of chromosome 1 containing the insertion sites (genomic positions: chr1:69,000,000-74,200,000; 5.2 Mb (A) and chr1: 175,300,000-180,500,000; 5.2 Mb (B); galGal5). RT weighted average (WA) values obtained after cells sorting into four S-phase fractions, BrdU pulse-labeled nascent strands (NS) immunoprecipitation and sequencing are shown. Early-replicated regions are represented in orange and late-replicating regions in blue. Below, track of eigenvector 1 values corresponding to A/B compartments at 100 kb resolution after Hi-C analysis in wt cells, track of replication origins determined in (Massip *et al*, 2019) (Ori peaks) and annotated genes are reported. The three sites chosen for insertion are indicated with red arrows and dotted lines (mid-late, late 1 (A) and late 2 (B) insertion).

At the bottom, an enlargement of late insertion sites (chr1: 69,500,000-71,500,000 (A), chr1: 177,000,000-179,000,000 (B); galGal5), displaying genes, mRNAs and ESTs for the chicken and all other species together with track of replication origins determined in (Massip *et al*, 2019) (Ori peaks) is shown. Tracks of RefSeq genes are represented in blue, tracks of Ensembl genes in red, tracks of AUGUSTUS ab initio gene predictions and TransMap alignements in green and tracks of mRNAs and ESTs in black. Insertion sites are indicated with red dotted lines and black dotted lines determine the borders of the enlarged regions.

Figure 8. Two late-replicating environments are permissive to a shift toward earlier replication after the site-specific insertion of a large autonomous replicon.

A, B. RT profiles of chromosomal alleles following the targeted integration of a β^A -globin+ β -actin construct into two late-replicating loci, 1 (A) and 2 (B) in two or three clonal cell lines respectively. Nascent strands (NS) were quantified by real-time qPCR in four S phase fractions. Specific primer pairs determine the RT profile for the modified allele (With), the wt allele (Without) and both alleles (Both). The endogenous β -globin locus was analyzed as an early-replicated control. The modified (Mod) and wild-type (wt) alleles are shown. Difference - Δ L+ Δ E values calculated at the target site following transgene integration are indicated (see Appendix Figure S1). Error bars correspond to the standard deviation for qPCR duplicates. The black vertical bars represent the precise insertion position.

Figure EV1. Additional RT assays for transgenes shifting the timing of replication.

A, B. RT profiles of each chromosomal allele are determined after targeted transgene integration using the allele-specific analysis of RT method by real-time PCR quantification described in Appendix Figure S1. Differences in - Δ L+ Δ E values calculated at the target site following transgene integration are indicated. Data information: (A, B) Blue triangles represent reactive *loxP* sites. Error bars correspond to the standard deviation for qPCR duplicates. Analysis of six β -actin clonal cell lines (A) or two β ^A-globin+ β -actin clonal cell lines (B) described in Figure 1 is reported. Black vertical bars represent insertion sites.

Figure EV2. One advanced replicon inserted at site 1 or at site 3 directs a shift to earlier replication independently of the presence of a *GFP* reporter construct inserted at site 2.

RT profiles of each chromosomal allele are determined after targeted transgene integration using the allelespecific analysis of RT method by real-time PCR quantification described in Appendix Figure S1. Differences in $-\Delta L + \Delta E$ values calculated at the target site following transgene integration are indicated.

A. Analysis of one clonal cell line containing one GFP reporter construct composed of the GFP reporter gene under the control of the β^A -globin promoter (β^A pro) and linked to a 1.6 kb fragment of human chromosome 7 (h.K7) inserted at site 2.

B, C. Analysis of clonal cell lines containing one β^A -globin+ β -actin construct described in Figure 1 inserted at site 1 and one *GFP* reporter construct inserted at site 2 on the same chromosome (B) or on the other chromosome (C).

D, E. Analysis of clonal cell lines containing one β^A -globin+ β -actin construct inserted at site 3 and one *GFP* reporter construct inserted at site 2 on the same chromosome (D) or on the other chromosome (E).

Data information: Blue and black triangles represent reactive loxP sites and recombined inactive loxP sites respectively. Black vertical bars represent insertion sites. Error bars correspond to the standard deviation for qPCR duplicates.

Figure EV3. Two β^A -globin+ β -actin constructs as well as two β -actin constructs inserted at sites 1 and 3 form an early-replicated domain.

A-C. RT profiles of each chromosomal allele are determined after targeted transgene integration using the allele-specific analysis of RT method by real-time PCR quantification described in Appendix Figure S1. Differences in - Δ L+ Δ E values calculated at the target site following transgene integration are indicated. Error bars correspond to the standard deviation for qPCR duplicates. (A, B) Analysis of two 1+2+3 (A) and three 1+3 (B) clonal cell lines described in Figure 3A. (C) Analysis of five clonal cell lines containing two β -actin constructs inserted at sites 1 and 3 on the same chromosome described in Figure 3B. Data information: Blue and black triangles represent reactive *loxP* sites and recombined inactive *loxP* sites


respectively. Black vertical bars represent insertion sites. Error bars correspond to the standard deviation for qPCR duplicates.


Figure EV4. The open chromatin structure of the whole advanced replicon is imposed by the active β -actin promoter.


A. Relative quantification, by real-time qPCR, of mRNA expression levels (RT-QPCR+) or background levels (RT-QPCR-), was performed in the β^A -globin and β^A -globin+ β -actin clonal cell lines. For relative quantification, mRNA levels were normalized against BUIA mRNA levels arbitrarily set at 100 (first table). Crossing point (Cp) values for RT-QPCR+ and RT-QPCR- experiments are reported in the second table. NA corresponds to non-amplified samples, NS to non-specific signals and LD to the limit of detection. B-D. The β^A -globin (B), β -actin (C) and β^A -globin+ β -actin (D) transgenes are shown on the left, with the positions of the amplicons used for quantification (thick black lines with names indicated above). The endogenous active MED14 promoter, two genomic regions located within the condensed region upstream from the β -globin locus (cond1 and cond2) were analyzed as controls. Quantification, by real-time qPCR, of total chromatin (input) extracted from the β^A -globin (B), β -actin (C) and β^A -globin+ β -actin (D) clonal cell lines after digestion with increasing concentrations of micrococcal nuclease (MNAse, 2.5U, 10U, 40U, 160U/mL). Error bars indicate the standard deviation for qPCR triplicates made on two independent clones. E. Immunoprecipitations of H3K9K27 acetylation (ac), H3K4 trimethylation (me3) or H3K4 dimethylation (me2) on formaldehyde-crosslinked chromatin extracted from the β^A -globin (green) and β^A -globin+ β -actin (purple) clonal cell lines. The endogenous active BUIA promoter (BUIA pro) was analyzed as a control. Data are presented as enrichments of immunoprecipitated material relative to input DNA and normalized against BU1A enrichment. Error bars indicate the standard deviation for at least qPCR duplicates made on two independent clones.


Figure EV5: Two β^A -globin constructs inserted at sites 1 and 3 are not sufficient to form an early-replicated domain.


RT profiles of each chromosomal allele are determined after targeted transgene integration using the allele-specific analysis of RT method by real-time PCR quantification described in Appendix Figure S1. Differences in $-\Delta L + \Delta E$ values calculated at the target site following transgene integration are indicated. Error bars correspond to the standard deviation for qPCR duplicates. Analysis of six β^A -globin (1+3) clonal cell lines described in Figure 4B.


























Α	Relative quantification values	BU1A gene	MED14 gene	5' 2xFIV-1	β ^A pro 2	II2R gene	3' 2xFIV-1	BsR gene		Figu
^	RT-QPCR β^{A} -glo bin line (1)	100	2.51	NS	NS	NS	NS	Dork gene		Ŭ
	+ β ^A -glo bin line (2)	100	2.58	NS	NS	NS	NS			
	RT-QPCR β^A -globin + β -actin line (1)	100	2.26	NS	0.097	0.091	LD	17		
	+ β^{A} -glo bin + β -actin line (2)	100	3.06	NS	LD	LD	NS	6.6		
		D.111.4	115511		ΔΔ Δ	"05	010 5874			
	Crossing point values	BU1A gene		5' 2xFIV-1	β ^A pro 2	II2R gene	3' 2xFIV-1	BsR gene		
	RT-QPCR β ^A -glo bin line (1) + β ^A -αlo bin line (2)	14.4	20	34.3	319	31.8	32.6			
	+ $β^A$ -glo bin line (2) RT-QPCR $β^A$ -glo bin line (1)	14.1 38.4	19.7 40.5	33.7 NA	32.1 33.1	31.9 33.4	33.9 32.9	-		
	- β ^A -glo bin line (1)	38.4	38.7	NA NA	NA	41.8	34.3			
	RT-QPCR β^{A} -globin + β -actin line (1)	14	19.8	31	23.9	24.3	28.4	16.6		
	+ β^{A} -glo bin + β -actin line (2)	14.4	19.7	33.9	29.1	29.3	31.2	18.4		
	RT-QPCR β^{A} -globin + β -actin line (1)	34.5	38.5	40.3	36.9	42.1	36.5	35.8		
	- $β^A$ -glo bin + β-actin line (2)	32.2	37.3	44.4	36.8	43.6	33.8	34.4		
	,		ઇ 9	3.5	-					_
B	^{BA} - <i>globin</i> Line			1	2.5 ∪					
	_		Whole chromatin (Input) ative to condensed regic	3.0				T		
	3 kb		= pe 6		160U			1		
5			5 ens	2.0						-
2xl	FIV pro gene 2xFIV 1+	-5kb	5 Pu 4	1.0	5	ф.		<u> </u>	•	
	2xFIV 1 - 2xFIV	-	ਦੂ ਨੂੰ 3	1 (ĬĬ ſŧĬŧ	- tt-t*	┲┸	╢┸╫	
Mod _	β ^A pro IL2R polyA		olo e te				▋▐ [▘]		<u> </u>	
	III p pio ilezk		1 <u>a</u> ig	0.5						*
Wt _		-	필 0	MED14 0.0	cond cond	1 1+5	kb 5'	1 2 1	L2R 3'	•
5	1 1+	-5kb		pro	1 2	Insertion sit	es 2xFIV —		ene 2xFIV	
				· · · · · ·	Controls		_	ion site modifie		-
C B	-actin Line		. 14							
C p	-aciiii Liile		Whole chromatin (Input) relative to condensed regions 0 7 9 9 0 15 :	2.5 U						
			but egi							
	3 kb		Whole chromatin (Input) ative to condensed regic 7 7 9 8 0 7	160U			l 			
	5' β-actin β-actin BsR		atin 8 suse				h———			
	p <u>ro</u> p <u>ro</u> <u>gene</u> 1 <u>+</u> 5k	(b	omo puge	∐'						
			15 8 .							
Mod .	β-act pro BsR	_	9e 0	 			.	—		
Wt .		_	Z III 2			. [*]				
į	500 bp — " —		> <u>e</u> 0				<u> </u>			
	1 1 +5k	b		MED14 cor		1 +5kb 5	β-actin β-ac			
				pro 1	11100	rtion sites	pro pro			
					Controls	Inser	tion site mod	lified allele		
D β	^A -globin+β-actin Line		18							-
Р	g.c.c p c.c =c		Whole chromatin (Input) relative to condensed regions 0 7 8 9 8 6 7 0 0 8 9 8 9 8 9 8 9 9 8 9 9 9 9 9 9 9 9 9	10 U						-
	6 kb		bot 14	₩ ■ 40 U						-
5'	$β^A$ IL2R 3' $β$ -actin BsR	,	= 12 - G = 12							-
2xFI			ot gatin					, 	h	-
-	2	_	omoonde 8					1 1		-
Mod	nolvA	- //	Chr C	l m			м. т (Н			-
	β^{A} pro $IL2R$ β^{B} β^{A} pro β^{B}		hole ive to	111144		Т і Щ.				_
Wt	0 bp 4		elati N Mi							-
30	^{0 bp} 1	1 +5kl	D & 0	MED14 cond	cond 1 1	+5kb 5'	1 2	IL2R 3' B	3-actin BsF	₹
				pro 1		sites 2xFIV	β^A pro	gene 2xFIV	pro gen	е
E	β^{A} -globin Line β^{A} -globin+ β -actin Lin	ne			Controls		Insertion s	site modified a	llele	_
		— 120 _□				25				
10 Polymort relative to <i>BU1A</i> promoter 10 Polymore 10	H3K9K27ac		- 1	H3K4me3	ī			H3K4me2	2 1	
D 110		100			<u> </u>	20				
4 60 L		80							4	
108 E						15		1	-	
의 50 의 40		60								
.≧ 30		40				. 10				
20 elati						5				1
± 10		20				· ~ ~ ~ ~				
± 0 [0				0		,		
ja Č E			U1A Insertion	5' β ^A	3' β- <i>acti</i>	n BU				β-actin
_	pro site 1 2xFIV pro 2 2xFIV p	ro	oro site 1	2xFIV pro 2	2 2xFIV pro	pr	o site 1	2xFIV pro 2	2 2xFIV	pro

BU1A Insertion pro site 1

Controls


Insertion site modified allele

Insertion site modified allele

Controls

Controls

Insertion site modified allele



APPENDIX

Clustering of strong replicators associated with active promoters is sufficient to establish an earlyreplicating domain

Caroline Brossas¹, Anne-Laure Valton², Sergey V. Venev², Sabarinadh Chilaka³, Antonin Counillon¹, Marc Laurent¹, Coralie Goncalves¹, Bénédicte Duriez¹, Franck Picard⁴, Job Dekker^{2,5} and Marie-Noëlle Prioleau¹*

Page 2-10: Appendix Figures S1-S9

Page 11-15: Appendix Table S1-S5

Page 16-21: Appendix Figure legends S1-S9


Page 21: Appendix Table legends S1-S5

Page 22: References

Α


1) Asynchronous cells are BrdU pulse labelled for 1h

2) S-phase cells are sorted by flow cytometry into 4 fractions (S1 to S4)



3) The nascent BrdU-labelled DNA is enriched by immunoprecipitation

4) and quantified with allele specific primer pairs by qPCR analysis



В

Method 1:

Proportion differences between early fractions and late fractions

$$\begin{cases} \Delta L = -27.3\% \\ \Delta E = +8.4\% \\ -\Delta L + \Delta E = 35.7\% \end{cases}$$


$$\Delta L = [(\%S3+\%S4)_{with}] - [(\%S3+\%S4)_{without}]$$

$$\Delta E = [(\%S1)_{with}] - [(\%S1)_{without}]$$
Global timing shift value: $-\Delta L + \Delta E$

Method 2:


C


Slope differences (∆slope) on four fractions between the modified and the Wt allele





Linear regression equations: y=-4.0066x+35.016 y=5.8147x+10.463

$$\Delta$$
slope = slope $_{With}$ - slope $_{Without}$












В

Α







Site of insertion	Number of clones and source	RT shift Median values
Mid-Late (1)	Total= 44	
2xFIV 2xFIV 2xFIV Wt 1	10 2 Hassan-Zadeh et al. 2012 (Figure 8) Valton et al. 2014 (Figure 8C, S10)	$-\Delta L + \Delta E = +6.5\%$
2xFIV 2xFIV Mod	8 2 Hassan-Zadeh et al. 2012 (Figure 6B) Valton et al. 2014 (Figure 8C, S9)	-ΔL+ΔE= +20.2%
Mod β-act pro BsR Wt 1	6 \begin{cases} 1 & Hassan-Zadeh et al. 2012 (Figure 4A) \\ 5 & This study \\ (Figure EV1A.) \end{cases}	-ΔL+ΔE=+19.6%
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	8 a Hassan-Zadeh et al. 2012 (Figure 6A) This study (Figure 64) EV1B.,EV2B-C.)	-ΔL+ΔE=+36.6%
Mid-Late (3)		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	3 { This study (Figure EV2D-E.)	-ΔL+ΔE= +26.8%
Mid-Late (1+3 and 1+2+3)		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	5 { This study (Figure EV3A-B.)	$-\Delta L + \Delta E = +65.2\%$
Mod β -act pro PuroR β -act pro BSR Wt $\frac{1}{3}$	5 This study (Figure EV3C.)	$-\Delta L + \Delta E = +38.5\%$
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	7 This study (Figure EV5)	-ΔL+ΔE=+11%
Late (1)		
2xFIV 2xFIV Mod — β ^A pro IL2R β-act pro BsR Wt — Late1	2 - This study (Figure 8A.)	-ΔL+ΔE= +29.3% / +51.7%
Late (2) 2xFIV Mod β ^A pro L2R DolyA β-act pro BsR Wt Late2	3 - This study (Figure 8B.)	$-\Delta L + \Delta E = +19.1\%$

	Construction tested / site	Both concentration	With concentration	Ratio With/Both
Insertions at site mid-1				
β-actin (1)		0.97	0.45	0.47
β-actin (2)		0.78	0.32	0.41
β-actin (3)	β- <i>actin /</i> 1	0.63	0.37	0.59
β-actin (4)		0.97	0.62	0.63
β-actin (5)		0.93	0.41	0.44
β ^A -globin+β-actin (1)		1.34	0.71	0.53
β ^A -globin+β-actin (2)		1.29	0.65	0.5
β ^A GFP h.K7+ $β$ ^A -globin+ $β$ -actin (1)	OA stabist 0 antin / 1	0.81	0.45	0.55
β ^A GFP h.K7+ $β$ ^A -globin+ $β$ -actin (2)	β ^A -globin+β-actin / 1	0.84	0.43	0.51
$\beta^{A}GFP$ h.K7+ β^{A} -globin+ β -actin (3)		0.74	0.4	0.54
β ^A GFP h.K7+ $β$ ^A -globin+ $β$ -actin (4)		0.91	0.45	0.49
LoxP_LE (1)	LoxP_LE / 1	0.58	0.28	0.48
Insertions at site mid-2				
β ^A <i>GFP</i> h.K7 (1)	β ^A GFP h.K7 / 2	1.12	0.54	0.49
Insertions at site mid-3	•			·
β ^A -globin+β-actin + $β$ ^A GFP h.K7 (1)		1.04	0.57	0.55
β ^A -globin+β-actin + $β$ ^A GFP h.K7 (2)	β ^A - <i>globin</i> +β- <i>actin</i> / 3	1.59	0.59	0.37
β ^A -globin+β-actin + $β$ ^A GFP h.K7 (3)		1.08	0.43	0.4
Insertions at site mid-1 and mid-3				
β ^A -globin+β-actin + $β$ ^A GFP h.K7+ $β$ ^A -		0.56	0.73	1.29
globin+β-actin (1)		0.00	0.70	1.20
β ^A -globin+β-actin + $β$ ^A GFP h.K7+ $β$ ^A -		0.54	0.58	1.07
globin+β-actin (2)		0.04	0.30	1.07
β ^A -globin+β-actin + $β$ ^A GFP h.K7+ $β$ ^A -	OA glabin 10 gatin / 1 and 3	1.15	1.33	1.16
globin+β-actin (3)	β^{A} -globin+ β -actin / 1 and 3	1.15	1.55	1.10
β ^A -globin+β-actin + $β$ ^A GFP h.K7+ $β$ ^A -		0.87	0.00	1 12
globin+β-actin (4)		0.07	0.99	1.13
β ^A -globin+β-actin + $β$ ^A GFP h.K7+ $β$ ^A -		0.00	0.04	4.40
globin+β-actin (5)		0.83	0.94	1.13
$β$ ^A -globin+β-actin +LoxP_LE (1)		3.34	2.21	0.66
$β$ ^A -globin+β-actin +LoxP_LE (2)	LoxP_LE / 1	2.19	1.39	0.63
β ^A -globin+β-actin +LoxP LE (3)	_	2.12	1.13	0.53
β-actin (1+3) (1)		1.17	0.71	0.61
β-actin (1+3) (2)		1.23	0.78	0.64
β-actin (1+3) (3)	β- <i>actin /</i> 3	1.22	0.7	0.57
β-actin (1+3) (4)	·	0.95	0.52	0.55
β-actin (1+3) (5)		1.04	0.57	0.54
β ^A -globin (1+3) (1)		0.65	0.63	0.97
β ^A -globin (1+3) (2)		0.74	0.62	0.83
β^{A} -globin (1+3) (3)		0.92	1.2	1.31
β ^A -globin (1+3) (4)	β ^A - <i>globin</i> / 1 and 3	0.77	1.0	1.30
β ^A -globin (1+3) (5)		0.75	0.66	0.88
β^{A} -globin (1+3) (6)		0.2	0.22	1.1
Insertions at site late-1		0.2	0.22	1.1
_	-	2.45	0.96	0.45
β^{A} -globin+ β -actin (1)	β ^A -globin+β-actin / late 1	2.15		0.45
β ^A -globin+β-actin (2)		1.71	0.75	0.44
Insertions at site late-2		4.0	0.50	0.07
$β^A$ -globin+β-actin (1)	Α , , , , , ,	1.6	0.59	0.37
β ^A -globin+β-actin (2)	β ^A -globin+β-actin / late 2	1.37	0.5	0.36
β ^A -globin+β-actin (3)		0.98	0.43	0.44

Primer name	Primer sequence	Insertion site	galGal5 Assembly	Amplicon size
5'am_ML1 3'am_MI1	(Hassan-Zadeh et al., 2012)	site mid-late 1	chr1:72,565,520	
5'am MI2 Up	CCAAACCAGGCACTCTTAGT			
5'am ML2 Low	AGTCACTIGGCATAAATAAGAAGCC	0 11 11 11 11	7.00	2,163 bp
3'am ML2 Up	CTGAGCAGGAAACGA	site mid-late z	Chri: 72,548,589	000
3'am_ML2_Low	CCATAGTGCAGACCTGGCAT			7,000 pp
5'arm_ML3_Up	ACACACTCACCTCCTGCCTT			2 OE4 bp
5'arm_ML3_Low	AGATCTCAGTCCTGCCAGCA	oito mid lato a	obr1. 72 536 060	4,00 4 pp
3'arm_ML3_Up	AAGTICGTAATACACAACCTIGAC	- אונפ וווומ-ומופ א	CIII 1. 72,330,000	2 060 5
3'arm_ML3_Low	GCTTCCCCGCTTCTTCCCTA			4,002 bp
5'arm_L1_Up	CAGTGAAACACAGGAACA			0 044 bp
5'arm_L1_Low	TAACTCCAAGAACGATCACTGC	0+0	chr1-70 523 640	2,244 Dp
3'arm_L1_Up	GGAAATGTCTTGAATCTCACAAAGG	אום שום	CIII 1.70, 323, 049	0 407 hp
3'arm_L1_Low	ATGCCCACCAGTGTCCATAA			4, 137 Up
5'am_L2_Up	ACTIGTIGAGCCTTTATGGAGAAC			1006
5'am_L2_Low	CGGTGTTACAGAGGAGTAAAACTGA	C otol otio	chr1-177 036 102	da ossi
3'am_L2_Up	ACCTIATGCATTTCGTTCCTATGT	אום ומום 7	011111111111111111111111111111111111111	2004
3'am_L2_Low	TAAGAAGAGAGATGAAAAC			ממו מס
2XFIV_β ⁴ <i>glob in-</i> Up	GGGGACAACTITGTATACAAAAGTTGAGGTGGCACGGGATCGCTTTCCTAGGTGGCACGGGATCGCTTTCCTCTGCCCACACCCTCCTG			
2XFIV_B ² globin-Low	GGGGACAACTITGTATAGAAAAGTIGGGTGGGTACCACTAGTGATGGTCCGTCATCCAGACATG			
2XFIV_β-actin-Up	GCTCGAGAGGTGGCACGGGATCGCTTTCCTAGGTGGCACGGGATCGCTTTCCTGTGAGC CCCACGTTCTGCTT			
2XFIV_ <i>β-actin-</i> Low	CTICTGTGGCTACTTCTAC			
Xhol+2xFIV-Up	GACTCTCGAGAGAAAGCGATCCCGTGCCACCTAGGAAAGCGATCCCGTGCCACCTGCTAGCCCTGATCAATAACT			
Xhol+2xFIV-Low	AAGTCCTCGAGCGTATTACAATTCACTGGCCGT			
β^-Up	CTGCCCACACCCTCCTG			
β ^A -Low	TTCCTGACCCTTGGGACCA			
GFP-Up	GGGTCAGGAAATGGTGAGCAAGGGCGAGG			
GFP-Low	TGAAGCAGCATTTACGCCTTAAG			
h.K7-Up	TECTGCTTCATTTCTGCTCTC			
h.K7-Low				
loxP_RE-h.K7-Up	GGATCCATAACTTCGTATAGCATACATTATGGAACGGTAACTTGAGCCCAGGAGTTCGA			
loxP_RE-h.K7-rev	AGAGTTCCAACCCCAGCCTC			

Beth or tale 2-3 8kb		Forward primer sequence	Reverse primer sequence	Genomic position (Build Dec 2015)
With on invention size				
With only-action	•			-b4-70540540-70540070
Willion of perform				CHF1:/2548543+/25486/6
Without or Will allele insention site 1				
Windood on Pire performs the 2				obr4:70565407:70565654
Willington CFFPreporter site 2				
Willington interaction site 3				CIII 1.72546545+72546676
Without of Wit alies insertion also late				chr1:72535996+72536105
Without or Will alies insertion alies late 2				
Controls				
Both or 181 - 14 8 M				
Bestin prise 2-3.8b	Both or 1+ 5 kb	TCCATACAGCCACAACAGCA	TGTGGAAGAGTTTCAGTCCAGG	chr1:72570952+72571067
Early immig centrol		TGTACTTCTCTGTGGACATGCA	TGGCACAGAGGACAGGTAAGA	chr1:70518727+70518810
Micropordia DNA GATECCA IGGAT ACTICCT GATECCA IGGAT CACCUTTOR S2.FIV-1 GSGCTATTCA COTTGAGA GTGGGCAGAGAGAGAGCAT FJD10 1 GSGGAGCAGAGAGAGCCAGAC GTGGGCAGAGAGAGAGCAT FJD10 1 GSGGAGCAGAGAGAGCCAGAC GTGGGCAGAGAGAGAGCCACAC GTGAGCAGTCCCCCACATCAG FJD10 1 GSGAGCAGAGAGCCCAGAC GTGAGCAGTCCCCCACATCAG FJD10 1 GSGAGCAGAGAGCCCAGAC GTGAGCAGTCCCCCACATCAG FJD11 1 GCATTCTAGCTTGAGTTCACT AACTGGGCGTGTGGGATCC LERG gene CTACACAGAGGTCCTGCTTGTTGC GTGAGAGAGAGCCTCAGGT GTGAGAGAGAGCCTCAGGT GTGAGAGAGAGCCTCAGGT GTGAGAGAGAGCCTCAGGT GAGAGTGAGAGAGAGCCTCAGGT GAGAGTGAGAGAGAGCCTCAGGT GAGAGTGAGAGAGAGCCTCAGGT GAGAGTGAGAGAGAGCCTCAGGT GAGAGTGAGAGAGAGACACACACACACACACACACACACA	Both or late 2 - 3.6kb	CAAGGTTTCCACCCCTAAAGA	TGATGGATGTGGGAAGAAA	chr1:177932452+177932533
Chips, Chromatin accessibility and RNA quantification GGCTATICAGCTIGITAG GCCACCTCAACTTTTGTATAC 5° 2#FW-3 TTATGCTGGCAGGACTGAGA GTGGGCAGGAGAGAGCGCTAG "pro 2 GGGAGAGGGCCAGAGAGC GTGGGCAGAGCTC "pro 2 GGGACTGCTCAGGTCATCA AATGTGGCGTGGGACAACTTGGAGA "pro 2 GGGACTGGTCAGGGTCATCA AATGTGGCTGTGGGATCAGCA "pro 2 GGGACTGGTCAGGGTCATCACA AATGTGGCTGTGGGATCAGACA "pro 2 GGGACTGCAGAGGGTCAGAGACACACTTGCACAACTTTGTAGAGAGAG				chr1: 194563998+194564262
SPEN-1 GGGCTATICAGCTIGTCTAG GCACCTCAACTITITATAC SPEN-13 TIATGCTGGCAGGAGTAGAA GTGGCAGAGAGAGAGAGAAGCCA Pip 01 GGGAGCAGAGAGCCCAGAC GTGAGCAGTCCCCACATCAG Pip 02 GGGAGTGCTCAGTCATCA AATGTGGCGTGTGGTCTC LER gene CTACACAGAGGTCTGCTG GTGAGAGAGAGAGCTCAGGGA 3 2xPIV-1 TSCATTCTAGTTCTAGTTTAGA ACCGTCACCACACTTGTATAGA 4 3 2xPIV-2 AAGCTTGATACACACAGGCTA ACCGTCACACACACTTTTAGA 5 3 2xPIV-3 AAGCTTGATACACACACAGGAGAGAGAGAGAGAGAGAGAG			GTAGTCCAGGCTTCACTTGA	chrM:541+731
Pip				
LRR gene				
37.2FN 1-3				
37.28	•			
Signation GTGGGATTCTTCTAAAGGCTA TGATCAATAACTTCGATAATGTCT				
BBR gene				
PuroR gene AGACCTTCCATGACCGAGT AGTTCTGCAGCTGACC				
If GPP GRAPTICGATAGCTIGAGGGG GRTDACTITIGGGCGTTTAC BFP gene GCCGCACAACCCTGAG GRTTACTITIGGCGTGTTCAC LNF AGGTTATCATTIGGTGGGCAGTCA LNF AGGTTATCATTIGGTGGCAGTCA LNF CCCCCTATAGTGTGAGTGGTATACA GTTTTAGTTTAG				
GEP gene				
INST INST INST INST INST INST INST INST				
LoxP site				
CATCTGTGCTCTGGGTCA				
Cond 2				chr1:194546368+194546497
BU1A gene AATGTCCCCAAATGACTCT CG GTGTCAGCTCAGCACTCTCC chrl 91922377-91922518 BU1A gene AATGTCCCCAAAATGAGCTG CCTCTTTTTCCACCCTCC chrl 919223737-91922517 MED 14 gene TGGGCTAATAATGCTGGAAAGGT TAGAGAGCCAGACGACCAGCCACCCTCCTC chrl 91923373-91922517 MED 14 gene TGGGCTAATAATGCTGGAAAGGT TAGAGAGCCAGACGACCAGACCA				chr1:194546457+194546563
BUTA gene AATGTCCCCAAAATGAGCTG CCTCTTTTTCCACCCTCCTC chrl 91923373941922517	MED 14 pro	GGATTCACACTGTTCCCCTCC	TGCATGTTTCTCTCATCCGAAGT	chr1:112227330+112227461
MED 14 gene TGGGCTAATAATGCTGGAAAGGT TAGAGAAGCCAGACGATCAGCA chr1:ft2236822 Long-range amplifications LR 1+2 AAGGGTCAGCTTTCGTGATAATCTGG ACCTCTTGCATTCACACT LR 1+2 Ctrl GCAAGATGGGCAGAGCTGAGTTAACAAT TGTCCTGTAAGTCCTGGCAAAACAAAGA chr1:72548824+72565503 LR 2+3 GAGCGTATTACAATTCACTGGCCGTC TGCTCACCATTTCCTGACCCTTG LR 2+3 ctrl GCAGTATAACAAGCAGCCGTGAAGTAAAA CAGTCTTATCCCTGCCTGG LR 2+3 ctrl GCAGTATAACAAGTCAGCCGTG CTGCTCACCATTTCCTGACCCTTG LR 1+3 GAGCGTATTACAATTCACTGGCCGTC GATCACCCTTCCTGATAG chr1:72536307+72548324 LR 1+3 GAGCGTATTACAATTCACTGGCCGTC GATCCCGTGCCACCTTCCTGATAG Chr1:72536307+72548324 LR 1+3 GAGCGTATTACAATTCACTGGCCGTC GATCCCGTGCCACCTTCACATTTTGTAT LAGAGAGACTGCCGTG CACCTTCAGTAG Chr1:72536307+72548324 LR 1+3 GAGCGTATTACAAATTCACTGGCCGTC GACCTGACACTTTTGTAT LAGAGAGACTTGGCGTG CACCTGACACTTTGTAT LAGAGAGACTGGCGTG CACCTGACACTTTGTAT LAGAGAGACTGGCGTGAGATTGGCGCGTC GACCTGACACTTTGTAT LAGAGAGACTGGCGCACCTGAACTTTTGTAT LAGAGAGACTGGCGCACCTGAACTTTGTATAGAAAA LAGAGACTGGCGCACCTGAACTTTGTATAGAAAAA LAGAGACTGGCGCACCACTTGATGAGAAA CACAAGA CACAAGACACAAGA CACAAGACACAAGACACACAC	BU1A pro	CTCTGTAGCCAGATCGTCTTCTC	GTGTCAGCTCATCTAGGCAAATC	chr1:91922377+91922546
LR1+2 AAGGTCAGCTTTCGTGATAATCTGG ACCTCTTGCATTCACAGTTCACA LR 1+2 ctrl GCAAGATGGGCAGAGCTGAGTTAACAAT TGTCCTGTAAGTCCTGGCAAAACAAAGA chr1:72548824+72565503 LR 2+3 GAGCGTATTACAATTCACTGGCCGTC CTTGCTCACCCTTG CTTGACTAACACCCTTG LR 2+3 ctrl GCAGTATAACAAGCACGCCTGAAGTAAACAAGTAAA CACTCTTATCCCACCCTTG LR 1+3 GAGCGTATTACAATTCACTGGCCGTC GATCCCACCCCTTAAGC LR 1+3 GAGCGTATTACAATTCACTGGCCGTC GATCCCACCCCTACACTTTTGTAT CACCCTTGCTAAGCATCCCTTGATAGCAGCCTGAAGCAGAGAAACAATAACACCCTTGAAGCACTGAAGCACTGAACTTTAGTCACTCGCCTTC LR 1+3 GAGCGTATTACAATTCACTGGCCGTC GACCTCTAACTTTGTAT LR 1+3 GAGCGTATTACAATTCACTGGCCGTC GACGTTCTGACTTTGTATCCTC LR 1+3 GAGCGTATTACAATTCACTGGCCGTC GACGTTTGAGTTGTACTC LR 1+3 GAGCGTATTACAATTCACTGGCCGTC GACGTTCTGACTTGTATACTC LR 1+3 CTCCAATTCGCCCTATAGTGAGTCGTA GATCCCGTGCCACCTCAACTTTTGTAT LR 1+3 ctrl GCAATTCGCCCTATAGTGAGTCGTA GATCCGTGGCACACTTTGTATAGAAAA LR 1+3 ctrl GCAATTCGCCCTATAGTGAGTCGTA GATCCGTGGCACACCTTTGTATAGAAAA LR 1+3 ctrl GCAATTCGCCCTATAGTGAGTCGTA GATCCGTGGCAAACAAGAA Chr1:72597486+72626682 Screening site 2 for GFP reporter GCTCCAATTCGCCCTATAGTGA GGCCTCCTCTCCTGGCAAAACAAAGA chr1:72597486+72626682 Screening-site 1 for β-qlobin+β-actin GGACTGCATGAGAGAAAGA TCTGCCTTCTCCCTGATAACG 5'-screening-site 1 for β-qlobin+β-actin GGACTGCAACAAAAGT TCTGCCTTCTCCCTGATAACG 5'-screening-site 1 for β-qlobin+β-actin GGACTGCAACAAAAATAA CCACATGTTTATTGCATACGGC 3'-screening-site 1 for β-qlobin+β-actin GAGCTCCAATTGCACTGAAACATAA CCACATGTTTATTGCATACGGC 3'-screening-site 1 for β-qlobin+β-actin GAGCTCCAATTGCACTGAAACATAA CCACATGTTTATTGCATACGGC 3'-screening-site 1 for β-qlobin+β-actin GAGCTCCAATTGCACTGGAACATAA CTACAGGTCTTGG 3'-screening-site 1 for β-qlobin+β-actin GAGCTCCAATTGCACTGGAACATAA CTACAGGTCTTGG 3'-screening-site 1 for β-qlobin+β-actin GAGCTCCAATTGCACTGGAACCTGAACCTGAACCTGAACCTGAACCTGAACCTGAACCTGAACCTGAACCTGAACCTGGAACCTGAACCTGAACCTGAACCTGAACCTGAACCTGAACCTGAACCTGAACCTGAACCTGGAACCTG	BU1A gene	AATGTCCCCAAAATGAGCTG	CCTCTTTTTCCACCCTCCTC	chr1:91923373+91923517
LR 1+2 MAGGGTCAGCTTTCGTGATAATCTGG ACCTCTCTTGCATTCACAGTTCAACAA LR 1+2 ctrl GCAAGATGGGCAGAGCTGAGTTAACAAT TGTCCTGTAAGTCCTGGCAAACAAAAAAAAAA	MED 14 gene	TGGGCTAATAATGCTGGAAAGGT	TAGAGAAGCCAGACGATCAGCA	chr1:112236082+112236823
LR 1+2 ctrl GCAAGATGGGCAGACTGAGTTAACAAT TGTCCTGTAAGTCCTGGCAAAACAAAGA chr1:72548824+72565503 LR 2+3 GAGCGTATTACAATTCACTGGCCGTC CTTGGTCACCATTTCCTGACCCTTG LR 2+3 ctrl GCAGTATAACAAGCACGCCTGAAGTAAA CAGTCTTTATCCACCCCTTGACCCTTG LR 1+3 GAGCGTATTACAATTCACTGGCCGTC GATCCCGTGCCACCCTTAACTGACTTTTGTAT LR 10xP LE(1)+ β [*] -globin+β-actin (3) GAGCGTATTACAATTCACTGGCCGTC GATCCCGTGCCACCTCAACTTTTGTAT LR 10xP LE(1)+ β [*] -globin+β-actin (3) GAGCGTATTACAATTCACTGGCCGTC GACGTTGTGGCTGTTGTAGTTTGACTC LR β [*] -globin (1+3) TCCAATTCGCCCTATAGTGAGTCGTA GATCCCGTGCCACCTCAACTTTTGTAT LR 1-3 ctrl GCACTTACAATTCACTGGCCGTA GATCCCGTGCCACCTCAACTTTTGTAT LR 1-3 ctrl GCACTTACAATTCACTGGCCTATAGTGAGTCGTAT GATCCGTCGACCACACTTTTGTATAACAACACCACCCTAACATTCACTGGCCTATAGTGAGTCGTAT GATCCGTCGACCACACTTTTGTATAGAAAA LR 1+3 ctrl GCACTATACAAGCACCCCTAAAGTGAAA TGTCCTGTGAAGCCACACTTTTGTATAGAAAA CACAATTCACTGGCCTATAGTGAGTCGTAT GATCCGTCGACCACACTTTTGTATAGAAAA CACAATTCACTGGCCTATAGTGAGTCGTAT GATCCGTCGACCACACTTTTGTATAGAAAA CACAATTCACTGGCCTATAGTGAGTGAGTGAACAACACACAC				
IR 2+3 GAGCGTATTACAATTCACTGGCCGTC IR 2+3 ctrl GCAGTATAACAAGCACGCCTGAAGTAAA CAGTCTTTATCCCACCCTTTCGTATAG GCAGTATAACAAGCACGCCTGAAGTAAA CAGTCTTTATCCCACCCCTTCCTGATAG Chr1.72536307+72548324 LR 1+3 GAGCGTATTACAATTCACTGGCCGTC GATCCCGTGCCACCCCAACTTTTGTAT CLR 1b*β*-globin+β-actin (3) GAGCGTATTACAATTCACTGGCCGTC GACCTTGTGGCTGTGTGTGTGTGTACTC CLR β*-globin (1+3) TCCAATTCGCCCTATAGTGAGTCGTA GATCCGCCTACACTTTTGTAT CTCAATTCGCCCTATAGTGAGTCGTA GATCCGTGCACCCTAACTTTGTATAGAAAA LR 1+3 ctrl GCAGTATAACAAGCACGCCTGAAGTAAAA TGTCCTGTAAGTCGACCAACTTTGTATAGAAAA CR 1+3 ctrl GCAGTATAACAAGCACGCCTGAAGTAAAA TGTCCTGTAAGTCCTGGCAAAACAAAGA Chr1.72597486+72626682 Screening-site 2 for GFP reporter GCTCCAATTCGCCCTATAGTGA GGCACTCCATTTCCACTCCCT 5'-screening-site 2 for β*-globin+β-actin GGACTGGCTAGGGAACAAGAG TCTGCCTTCTCCCTGATAACG 5'-screening-site 1 for β*-alobin+β-actin GGACTGGCTAGGGAACAAGAG TCTGCCTTCTCCCTGATAACG 3'-screening-site 1 for fb-alobin+β-actin CCCCCTGAACCTGAAACATAA CCACATGTTATTGCATACGG 3'-screening-site 1 for fb-alobin+β-actin GCCCCTGAACCTGAACATAA CTCCAACCAGGCCACTTGG 3'-screening-site 1 for fb-alobin+β-actin GACCTCCAATTCGCCCTAT GGACTCCCATTGGAGCACTTAGTG GACCTCCAATTCGCCCTAT GCCTTCTCCCTGATACGG CCCCTGAACCTGAACCATAA CTCCAACCAGGCCACTTGG S'-screening-site 1 for fb-alobin+β-actin GACCTCCAATTCGCCCTAT GCCCCTGAACCTGAACCATAA CTCCAACCAGGCCACTTGG GCCCCTGAACCTGAACCATAA CTCCAACCAGGCCACTTGG GCCCCCTGAACCTGAACCATAA CTCCACCAGGCCACTTTGG CCCCTGAACCTGAACCATAA CTCCACCAGGCCACTTTGG GCCCCTGAACCTGAACCATAA CTCCCACGCCCCTCCTTTGCTGG CCCCTGAACCTGAACCATAA CTCCCAGGCCACTTCGCCCTAT GCTCTGCACCCTGGAGG CTCCCCTGAACCTGAACCATAA CTCCCAGGCCACTTCCTCCTGT GCTCGAGAGGCTCTCCTGTGGA CTCCCCTGGAGCCTTCTTGCTC CCCCTGAACCTGAACCATAA CTCCCAGGCCACTTTCTCCCTGT GCTCGAGAGGCTCTTCCTGGA CTCCCCCCGGAGCCTATAGTTGGCCTCATTGTTCTCC GGTCTGAGAGGTCTTCCTGGA CTCCCCCCGGAGCCTGAACCATAA CTCCCAGGCCACTTCCAGACC CCCCCGGAACCTGAACCATAA CACCCAGGCCACTTTCACGCCTAT GCCCCCCTGAACCTGAACCATAA CACCCAGGCCACTTTCCAGCACAC CCCCCCGGAACCTGAACCATAA CACCCAGGCACTTTCCAGCACC CCCCCTGAACCTGAACCATAA CACCCCAGGCCACTTTCCAGCACC CCCCCTGAACCTGAACCATAA CACCCAGGCACTTTCC				
LR 2+3 ctrl GCAGTATAACAAAGCACCGCTGAAGTAAA CAGTCTTATCCCACCCCTTATAG chr1:72536307+72548324 LR 1+3 GAGCGTATTACAATTCACTGGCCGTC GATCCCGTGCCACCCTCAACTTTTGTAT LR loxP LE(1)+ β'-globin+β-actin (3) GAGCGTATTACAATTCACTGGCCGTC GACCTTGGCTGTTGTAGTTGACTC LR β'-globin (1+3) TCCAATTCGCCCTATAGTGAGTCGTA GATCCCGTGCCACCTCAACTTTTGTAT LR β-actin (1+3) CTCCAATTCGCCCTATAGTGAGTCGTA GATCCGTGCACCCTCAACTTTTGTAT LR 1-3 ctrl GCAGTATAACAACACACGCCTCAAGTGAGTCGTA GATCCGTGCACCCTAACTTTGTAT CTCCAATTCGCCCTATAGTGAGTCGTAT GATCCTGGCACCACACTTTTATAGAAAA LR 1+3 ctrl GCAGTATAACAACACACGCCCCTGAAGTAAA TGTCCTGGCAAAACAAAGA Chr1:72597486+72626682 Screening of targeted integration 3'-screening-site 2 for GFP reporter GCTCCAATTCGCCCTATAGTGA GGCACCACACTTTCCATCTCCT 5'-screening-site 2 for β'-globin+β-actin GGACTGGCTAGGGAACAAAGA TCTGCCCTGATAACG 5'-screening-site 1 for β'-globin+β-actin GGACTGGCTAGGGAACAAAAGA TCTGCCCTGATAACG 3'-screening-site 1 for β'-globin+β-actin CCCCCTGAACCTGAACATAA CCACATGTTTATTGCATACCGC 3'-screening-site 1 for β'-globin+β-actin CCCCCTGAACCTGAACATAA CTTCCACCCAGGCCACTTTCG 3'-screening-site 1 for loxP LE CCAATTCGCCCTATAGTGAGTCG ACGTAACATAA CTTCCACCCAGGCCACTTTGG 3'-screening-site 1 for loxP LE CCAATTCGCCCTATAGTGAGTCG ACGTAACATAA CTTCCACCCAGGCCACTTTGG 3'-screening-site 1 for loxP LE CCAATTCGCCCTAT GATCGCCTAT ACTCCCCTCGATACCTGACCTG				chr1:72548824+72565503
LR 1+3 GAGCGTATTACAATTCACTGGCCGTC GATCCCGTGCCACCTCAACTTTTGTAT LR low LE(1)+ β ^A -globin+β-actin (3) GAGCGTATTACAATTCACTGGCCGTC GACGTTGTGGCCTGTAGTTGTAGTCC GACGTTGTGGCCTCAACTTTTGTAT LR β ^A -globin (1+3) CTCCAATTCGCCCTATAGTGAGTCGTA GATCCCGTGCCACCTCAACTTTGTAT LR β-actin (1+3) CTCCAATTCGCCCTATAGTGAGTCGTA GATACCAGCGCACACCTTGATAGAAAA LR 1+3 ctrl GCAGTATAACAAGCACCCCTGAAGTAAAA TGCCTGTGAGCCACAACAAAAAA Chr1:72597486+72626682 Screening of targeted integration 3'-screening-site 2 for GFP reporter GCTCCAATTCGCCCTATAGTGA GGACTGCCTATAGTGA GGACTCCATTTCCATCCCT 5'-screening-site 1 for β ^A -globin+β-actin GGACTGCCTAGAGGAACAAGAG TCTGCCTTCTCCCTGATAACG 5'-screening-site 1 for β ^A -globin+β-actin GGACGCTACAGTGGATAAAAA CCACATGTTTATTGCATACGG 3'-screening site 1 for lox P LE CCACATTCGCCCTATAGTGA CCACATGTTTATTGCATACGG 3'-screening site 1 for lox P LE CCAATTCGCCCTATAATGAGTCC 3'-screening site 1 for lox P LE CCAATTCGCCCTATAATGAGTCC 3'-screening site 1 for lox P LE CCAATTCGCCCTATAATGAGTCC 3'-screening site 3 for PuroR CCCCCTGAACCTGAAACATAA CTCCAACCAGGCACTATG 3'-screening site 1 for β ^A -globin+β-actin GAGCTCCAATTCGCCCTAT GCCCTCTATACCCTTGCCTGTTG 3'-screening site 1 for β ^A -globin+β-actin GAGCTCCAATTCGCCCTAT CCCCCTGAACCTGAACATAA CTCCAACCCAGGCACTATG 3'-screening site 1 for β ^A -globin+β-actin GAGCTCCAATTCGCCTAT CCCCCTGAACCTGAAACATAA CTCCACCCACCCAGCACTATG 3'-screening site 1 for β ^A -globin+β-actin GAGCTCCAATTCGCCCTAT GGCTGAACCTAACCTGCACTGGGAG BSR excision at site 2 CCCCCTGAACCTGAAACATAA TATCCCACTGCCACTGGGAG Ctrl ACCATGCAGGGCAGCTACAAC TGAGTTACCTTACCT				
LR loxP LE(1)+ β ^A -globin+β-actin (3) GAGCGTATTACAATTCACTGGCCGTC GACCTTGTGGCTGTTGTAGTTGTACTC LR β ^A -globin (1+3) TCCAATTCGCCCTATAGTGAGTCGTA GATCCGGTGCCACCTCAACTTTGTAT LR β-actin (1+3) CTCCAATTCGCCCTATAGTGAGTCGTAT GATACCGTCGACCAACTTTGTATAGAAAA LR 1+3 ctrl GCAGTATAACAAGCACGCCTGAAGTAAA TGTCCTGTAAGTCTGGCAAAACAAAAA chr1:72597486+72626682 Screening of targeted integration 3-screening-site 2 for GFP reporter GCTCCAATTCGCCCTATAGTGA GGCACTCCATTTCCATCTCCT 5'-screening-site 3 for β ^A -globin+β-actin GGACTGGCTAGGGAACAGAG TCTGCCTTCTCCCTGATAACG 5'-screening-site 1 for β ^A -globin+β-actin GTGCAGCATCAGTGGATAAAGT TCTGCCTTCTCCCTGATAACG 3'-screening site 1 for β ^A -globin+β-actin CCCCCTGAACCTGAAACATAA CCACATGTTATTATGCATACGGC 3'-screening site 3 for PuroR CCCCCTGAACCTGAACATAA CTTCCAACCCAGGCCACTATG 3'-screening site 1 for β ^A -globin+β-actin GAGCTCCAATTCGCCCTAT ACTAACAAATCACAGGCTACAGGGCACTATG 3'-screening site late 1 for β ^A -globin+β-actin GAGCTCCAATTCGCCCTAT ACTATTGTACCCTCCCTGTTG 3'-screening site late 1 for β ^A -globin+β-actin GAGCTCCAATTCGCCCTAT GCTCTGACCTGGAGG Screening site late 1 for β ^A -globin+β-ac				chr1:72536307+72548324
LR β²-globin (1+3) TCCAATTCGCCCTATAGTGAGTCGTA GATCCCGTGCCACCTCAACTTTTGTAT LR β²-actin (1+3) CTCCAATTCGCCCTATAGTGAGTCGTAT GATACCGGCGACCAACTTTGTATAGAAAA LR 1+3 ctrl GCAGTATAACAAGCACGCCTGAAGTAAA TGTCCTGTAAGTCCTGGCCAAACAAGAA chr1:72597486+72626682 Screening of targeted integration 3'-screening-site 2 for GFP reporter GCTCCAATTCGCCCTATAGTGA GGCACTCCATTTCCATCTCT 5'-screening-site 3 for β²-globin+β-actin GGACTGGCTAGGGAACAAGAG TCTGCCTTCTCCCTGATAACG 5'-screening-site 1 for β²-globin+β-actin GGACTGGCTAGGGAACAAGAT TCTGCCTTCTCCCTGATAACG 3'-screening-site 1 for β²-globin+β-actin GCCCCTGAACCTGAACATAA CCACATGTTTATTGCATACGG 3'-screening site 1 for loxP LE CCAATTCGCCCTATAGTGAGTCG ACGTAACAAATCTACAGGTCTTCG 3'-screening site 3 for PuroR CCCCCTGAACCTGAACATAA CTTCCAACCCAGGCCACTATG 3'-screening site late 1 for β²-globin+β-actin GAGCTCCAATTCGCCCTAT ACTATTGACCCTCCTGTTG 3'-screening site late 2 for β²-globin+β-actin GAGCTCCAATTCGCCCTAT GGTCTGATCCCTCTGTGG Screening site 2 grows a site 2 CCCCCTGAACCTGAACATAA TATCCCACTGCCACTGGGAGG PuroR excision at site 3 TGCATTCTAGTTGGTTTGCT GGTCTGAGAGGTCTTGTGGA		·		
LR β-actin (1+3)				
LR 1+3 ctrl GCAGTATAACAAGCACGCCTGAAGTAAA TGTCCTGTAAGTCCTGGCAAAACAAGA chr1:72597486+72626682 Screening of targeted integration 3'-screening-site 2 for β'-globin+β-actin GGACTGGCTAGGGAACAAGG TCTGCCTTCTCCTGATAACG 5'-screening-site 1 for β'-qlobin+β-actin GTGCAGCTAGTGGATAAAGT TCTGCCTTCTCCTGATAACG 5'-screening-site 1 for β-alobin-β-actin CCCCCTGAACCTGAACATAA CCACATGTTATTGCATACGGC 3'-screening-site 1 for losP LE CCAATTCGCCCTATAGTGA CCACATGTTATTGCATACGGC 3'-screening site 1 for losP LE CCAATTCGCCCTGAACATAA CCACATGTTATTGCATACGGC 3'-screening site 3 for PuroR CCCCCTGAACCTGAACATAA CTTCCACCCAGGCCACTATG 3'-screening site 1 for β'-alobin-β-actin GAGCTCCAATTCGCCCTAT 3'-screening site 1 for β'-alobin-β-actin GAGCTCCAATTCGCCCTAT ACTGCCCTATGTACGGCC 3'-screening site 1 for β'-alobin-β-actin GAGCTCCAATTCGCCCTAT ACTGCCCTATGTACCCCCTCCCTGTTG 3'-screening site 1 site 2 for β'-alobin-β-actin GAGCTCCAATTCGCCCTAT ACTGCCCTATCCACTGGCCACTGGAGCACTGGAGCCACTATG GAGCTCCAATTCGCCCTAT ACTGCCCTATCCACTGG Screening site specific excision BSR excision at site 2 CCCCCTGAACCTGAAACATAA TACCCCACGCCACTGGAGG PuroR excision at site 3 TGCATTCTAGTTGTGGTTTGTCC GGTCTGAGATTGCCTGT Chr1:72535815+72565623 Ctrl ACCAAGGCAGGCTACAAAC TGCCCTATTGCATTGCCTGT Chr1:72535815+72565623 Ctrl ACCAAGGCAGGCTACAAAC TGCCCAATTGCCCTATTCCACTGC Chr1:72535815+72565623 Ctrl ACCAAGGCAGCTCCAAGACCTGAAACATAA GCAGCCTTCCACTGGAC Chr1:72565577+72567483 No PuroR excision ACCACCTGAACCTGAACCATAA GCAGCCTTCCAGACC BSR excision CACGCCACATTCAAGCCATG TCCAGCAGCC BSR excision CACGCCACATTCAAGCCATG TCCAGCAAGACCTCTCAGACC BSR excision CACGCCACATTCAAGCCATG TCCAGCAGCC COOP number quantification loxP LE CGCCCTATAGTGAGTCGTATTACA TGTTTAAATGTTTGTAGCCTGCCT				
Screening of targeted integration 3'-screening-site 2 for GFP reporter GCTCCAATTCGCCCTATAGTGA GGCACTCCATTTCCATCTCCT 5'-screening-site 3 for β^-globin+β-actin GGACTGGCTAGGGAACAAGAG TCTGCCTTCTCCCTGATAACG 5'-screening-site 1 for β β'-globin+β-actin CCCCCTGAACCTGAAACATAA TCTGCCTTCTCCCTGATAACG 3'-screening-site 1 for β-actin CCCCCTGAACCTGAAACATAA CCACATGTTTATTGCATACGGC 3'-screening site 1 for loxP LE CCAATTCGCCCTATAGTGAGTCG ACGTAACAAATCTACAGGTCTTCG 3'-screening site 3 for PuroR CCCCCTGAACCTGAAACATAA CTTCCAACCCAGGCCACTATG 3'-screening site late 1 for β'-globin+β-actin GAGCTCCAATTCGCCCTAT ACTATTGTACCCCTCCTGTTG 3'-screening site late 2 for β'-globin+β-actin GAGCTCCAATTCGCCCTAT GGTCTGATCCCTACTCACTGG Screening site specific excision Screening of site specific excision ACCCCAGGACCTGAACATAA TATCCCACTGCCACTGGAGG PuroR excision at site 2 CCCCCTGAACCTGAACATAA TATCCCACTGCCACTGGAGG Chr1:72535815+72565623 Ctrl ACCCAAGGCAGCACACACA TGAGTTACTTTTCGCTTTCCACTGC Chr1:72535815+72565623 Ctrl ACCCAGGCAGCTACAAAC TGAGTTACTTTTCGCACTGGAACC Chr1:72565577+72567483 No BsR excision ACGCCCTGAACCTGAACCTGAACC TGCAGCAGAGCCTCTCAGACC<				obr1:72507496±72626692
3'-screening-site 2 for GFP reporter GCTCCAATTCGCCCTATAGTGA GGCACTCCATTTCCATCTCCT 5'-screening-site 3 for β'-globin+β-actin GGACTGGCTAGGGAACAAGAG TCTGCCTTCTCCCTGATAACG 5'-screening-site 1 for β'-globin+β-actin CCCCCTGAACCTGAAACAT CCACATGTTATTGCATACGG 3'-screening-site 1 for β'-globin+β-actin CCCCCTGAACCTGAAACATAA CCACATGTTTATTGCATACGGC 3'-screening site 1 for loxP LE CCAATTCGCCCTATAGTGAGTCG 3'-screening site 3 for PuroR CCCCCTGAACCTGAAACATAA CTTCCAACCCAGGCCACTATG 3'-screening site 1 for β'-globin+β-actin 3'-screening site 1 ate 1 for β'-globin+β-actin 3'-screening site 1 ate 1 for β'-globin+β-actin GAGCTCCAATTCGCCCTAT GAGCTCCAATTCGCCCTAT GCTCTAACCCAGGCCACTATG 3'-screening site 1 ate 2 for β'-globin+β-actin GAGCTCCAATTCGCCCTAT GGTCTGATCCCTACTCACTGG Screening of site specific excision BSR excision at site 2 CCCCCTGAACCTGAAACATAA TATCCCACTGCCACTGGAGG PuroR excision at site 3 GGATTCTGGTTGCCTCATTGAT TGCTTGCTAGAAGTTTGCTGGA Large 1+3 excision Up/Low GGTTCTGGTGCCCTCATTGAT TGCTCTGCTAGAATTGCCTGT Chr1:72535815+72565623 No PuroR excision CCCCCTGAACCTGAAACATAA CCACAAGGCAGGCTACAAAC TGAGTTACTTTTCATC Chr1:72535815+72565577+72567483 No PuroR excision ACGACCTTCCATGACCTGAACATAA GCAGCCACATTCAAACCATG CCCCTGAACCTGAACCTGAACATAA GCAGCCTTTTCCAGCAGACC BSR excision CCCCCTGAACCTGAACCATGA CCCCCTGAACCTGAACCATGACCATGACC COCCTGAACCTGAACCATGAACCATG CCCCTGAACCTGAACCATGAACCATG CCCCTGAACCTGAACCATGAACCATG CCCCTGAACCTGAACCATGAACCATG CCCCTGAACCTGAACCATGAACCATG CCCCTGAACCTGAACCATGAACCATG CCCCTGAACCTGAACCATGAACCATG CCCCCTGAACCTGAACCATGAACCATG CCCCCTGAACCTGAACCATGAACCATG CCCCCTGAACCTGAACCATGAACCATG CCCCCTGAACCTGAACCATGAACCATG CCCCCTGAACCTGAACCATGAACCATG CCCCCTGAACCTGAACCATGAACCATG CCCCCTGAACCTGAACCATGAACCATG CCCCCTGAACCTGAACCATGAACCATG CCCCCTGAACCTGCACTGAACCATGAACCATG CCCCCTGAACCTGCACTGAACCATGAACCATG CCCCCTGAACCTGCACTACAACCATG CCCCCTGAACCTGCACTACAACCATG CCCCTGAACCTGCACTACAACCATG CCCCCTGAACCTGCACTACAACCATG CCCCCTGAACCTGCACTACAACCATG CCCCCTGAACCTGCACTACAACCATG CCCCCTGAACCTGCACTACAA		JGCAGTATAACAAGCACGCCTGAAGTAAA	I G I C C I G I A A G I C C I G G C A A A C A A G A	CIII 1.72597460+72020062
5'-screening-site 3 for β^A-globin+β-actinGGACTGGCTAGGGAACAAGAGTCTGCCTTCTCCCTGATAACG5'-screening-site 1 for β^A-globin+β-actinGTGCAGCATCAGTGGATAAAGTTCTGCCTTCTCCCTGATAACG3'-screening-site 1 for β-actinCCCCCTGAACCTGAAACATAACCACATGTTATTGCATACGGC3'-screening site 1 for loxP LECCAATTCGCCCTATAGTGAGTCGACGTAACAAATCTACAGGTCTTCG3'-screening site 3 for PuroRCCCCCTGAACCTGAAACATAACTTCCAACCCAGGCCACTATG3'-screening site late 1 for β^A-globin+β-actinGAGCTCCAATTCGCCCTATACTATTGTACCCCTCCTGTTG3'-screening site late 2 for β^A-globin+β-actinGAGCTCCAATTCGCCCTATGGTCTGATCCCTATCTCACTGGScreening of site specific excisionScreening of site specific excisionATATCCCACTGCCACTGGAGGBSR excision at site 2CCCCCTGAACCTGAACATAATATCCCACTGCCACTGGAGPuroR excision up/LowGGTTCTGGTGCCCTCATTGATTGCTCTGCTAGAATTGCCTGTchr1:72535815+72565623CtrlACCCAAGGCAGGCTACAAACTGAGTTACTTTGGCATTACTTTTCATCchr1:72535815+725655623CtrlACCCAAGGCAGGCTACAAACTGAGTTACTTTGGCATTACTTTTCATCchr1:72565577+72567483No PuroR excisionCCCCCTGAACCTGAACATAAGCAGCCTTTTCCAGCAGACCNo BSR excisionACGCCACATTCAAAGCCATGTCCAGCAAGACCTCCAGACCPuroR excisionCACGCCACATTCAAAGCCATGTCCAGCAAGACCTCTCAGCCCopy number quantificationCAGCCCTATAGTGAGTCGTATTACATGTTTAAATGTTTGAGCCTGCCTloxP LECGCCCTATAGTGAGTCGTATTACATGTTTAAATGTTTGAGCCTGCCT		GCTCCAATTCGCCCTATAGTGA	GGCACTCCATTTCCATCTCCT	
5'-screening-site 1 for β^-globin+β-actinGTGCAGCATCAGTGGATAAAGTTCTGCCTTCTCCCTGATAACG3'-screening-site 1 for β-actinCCCCCTGAACCTGAACCATAACCACATGTTTATTGCATACGGC3'-screening site 1 for loxP LECCAATTCGCCCTATAGTGAGTCGACGTAACAAATCTACAGGTCTTCG3'-screening site 3 for PuroRCCCCCTGAACCTGAAACATAACTTCCAACCCAGGCCACTATG3'-screening site 1 for β^-clobin+β-actinGAGCTCCAATTCGCCCTATACTATTGTACCCCTCCCTGTTG3'-screening site late 2 for β^-clobin+β-actinGAGCTCCAATTCGCCCTATGGTCTGATCCCTACTCACTGG3'-screening of site specific excisionGAGCTCCAATTCGCCCTATGGTCTGATCCCTACTCACTGGBSR excision at site 2CCCCCTGAACCTGAAACATAATATCCCACTGCCACTGGAGGPuroR excision up/LowGGTTCTGGTGCCCTCATTGATTGCTCTGCTAGATTGCTGTchr1:72535815+72565623CtrlACCCAAGGCAGGCTACAAACTGAGTTACTTTGGCATTACTTTTCATCchr1:72535815+72565623CtrlACCCAAGGCAGGCTACAAACTGAGTTACTTTGGCATTACTTTTCATCchr1:72565577+72567483No PuroR excisionCCCCCTGAACCTGAACCTGAACATAAGCAGCCTTTTCCAGCAAGACNo BSR excisionACGCCACATTCCATGACCGAGTAGTTCTTGCAGCTCGGTGACPuroR excisionCAGCCACATTCAAAGCCATGTCCAGCAAGACCTCCAGACCSSR excisionCAGCCGACATTCAAAGCCATGTCCAGCAAGACCTCTCAGACCCopy number quantificationCAGCCCATATAGTGAGTCGTATTACATGTTTAAATGTTTGTAGCCTGCCTloxP LECGCCCTATAGTGAGTCGTATTACATGTTTAAATGTTTGTAGCCTGCCT				
3'-screening-site 1 for β-actin CCCCCTGAACCTGAAACATAA CCACATGTTTATTGCATACGGC 3'-screening site 1 for loxP LE CCAATTCGCCCTATAGTGAGTCG ACGTAACAAATCTACAGGTCTTCG 3'-screening site 3 for PuroR CCCCCTGAACCTGAAACATAA CTTCCAACCCAGGCCACTATG 3'-screening site late 1 for β'-alobin+β-actin GAGCTCCAATTCGCCCTAT ACTATTGTACCCCTCCCTGTTG 3'-screening site late 2 for β'-alobin+β-actin GAGCTCCAATTCGCCCTAT GACTCGCCTAT GACTCGCCTATCGCCCTGCACTGGAGGCCCCTCATTGATCGCCTTGCTGGAACCTGAAACATAACCCCCCCC				
3'-screening site 1 for loxP LE CCAATTCGCCCTATAGTGAGTCG ACGTACAAATCTACAGGTCTTCG 3'-screening site 3 for PuroR CCCCCTGAACCTGAAACATAA CTTCCACCCAGGCCACTATG 3'-screening site late 1 for R ^A -globin+B-actin GAGCTCCAATTCGCCCTAT ACTATTGACCCCTCCCTGTTG 3'-screening site late 2 for R ^A -globin+B-actin GAGCTCCAATTCGCCCTAT GTCTGATCCCTATCTCACTGG Screening of site specific excision BSR excision at site 2 CCCCTGAACCTGAAACATAA TATCCCACTGCCACTGGAGG PuroR excision at site 3 TGCATTCTAGTTGTGGTTTGTCC GGTCTGAGAGTTTGCTGGAACTTGAT TGCTCTGCTAGAATTGCCTGT Chr1:72535815+72565623 Ctrl ACCCAAGGCAGGCTACAAAC TGAGTACTTTGGCATTGCTGT Chr1:72535815+72565623 Ctrl ACCCAAGGCAGGCTACAAAC TGAGTTACTTTTCATC Chr1:72565577+72567483 No PuroR excision CCCCCTGAACCTGAACATAA GCAGCCTTTCCAGCAGAGC No BSR excision ACGCCACATTCAAACCATG TCCAGCAGGTACCAGACC BSR excision CAGCGCACATTCAAAGCCATG TCCAGCAGACCTCTCAGACC COpy number quantification LCCCCTAACTGAGGGAGTCGTATTACA TGTTTTGATTTTCTGGCC CGCCTATAGTGAGGAGAGAGTATACACCTGACCCAGCC CGCCCTATAGTGAGGAGAGAGAGAGAGAGAGAGAGAGAGA				
3'-screening site 3 for PuroR CCCCCTGAACCTGAAACATAA CTTCCAACCCAGGCCACTATG 3'-screening site late 1 for \$\beta^{A}\$-qlobin+\$\beta\$-actin GAGCTCCAATTCGCCCTAT ACTATTGTACCCCTCCTGTTG 3'-screening site late 2 for \$\beta^{A}\$-qlobin+\$\beta\$-actin GAGCTCCAATTCGCCCTAT GGTCTGATCCCTATCTCACTGG Screening of site specific excision BSR excision at site 2 CCCCCTGAACCTGAAACATAA TATCCCACTGCCACTGGAGG PuroR excision at site 3 TGCATTCTAGTTGTGGTTTGTCC GGTCTGAGAGGTCTTGCTGGA TGCTCTGGTAGATTGCCTGT Chr1:72535815+72565623 Ctrl ACCCAAGGCAGGCTACAAAC TGAGTTACTTTGGCATTACTTTTCATC Chr1:72535815+72565623 CCCCTGAACCTGAAACATAA GCAGCCTTTTCAGTTGCATTACTTTTCATC Chr1:72565577+72567483 No PuroR excision CCCCTGAACCTGAAACATAA GCAGCCTTTTCCAGCAAGAC No BSR excision ACGACCTTCCATGACCAGGT AGTTCTTGCAGCTAGACC PuroR excision CACGCCACATTCAAAGCCATG CAGCCAAGACCTCTCAGACC GGCATGGTTTTGATTTCTGGCC Copy number quantification In XP LE CGCCCTATAGTGAGTCGTATTACA CTTCCAACCCAGGCCACTTTCAAGTCGTATAA CTTCCAACCCAGGCCACTTTCAAGTCGAGT ACTATTGTACCCTTCATGACC GGTCTGATCCTTGAGGCCCTCGTTAGTCGGCC TCCAGCAAGACCTCTCAGACC GGCATGGTTTTGATTTCTGGCC COpy number quantification In XP LE CGCCCTATAGTGAGTCGTATTACA CTTCCAACCCAGGCCACTTTGACCACTGACCTGTTAGTCTTTTCATTTCTGGCC TGTTTAAATGTTTGTAGCCTGCCT				
3'-screening site late 1 for \$\textit{B^-alobin+\textit{B}-actin}\$ 3'-screening site late 2 for \$\textit{B^-alobin+\textit{B}-actin}\$ GAGCTCCAATTCGCCCTAT GGTCTGATCCCTACTGG Screening of site specific excision BSR excision at site 2 CCCCCTGAACCTGAAACATAA TATCCCACTGCCACTGGAGG PuroR excision at site 3 TGCATTCTAGTTGTGGTTTGTCC GGTCTGAAGGTCTTGCTGGA Large 1+3 excision Up/Low GGTTCTGGTGCCCTCATTGAT TGCTCTGCTAGAATTGCCTGT Chr1:72535815+72565623 Ctrl ACCCAAGGCAGGCTACAAAC TGAGTTACTTTGGCATTACTTTTCATC Chr1:72535815+72565523 CCCCTGAACCTGAAACATAA GCAGCCTTTTCAGCATACTTTTCATC Chr1:72565577+72567483 No PuroR excision CCCCCTGAACCTGAAACATAA GCAGCCTTTTCCAGCAAGAC No BSR excision ACGACCTTCCATGACCAGAT AGTTCTTGCAGCAGACC PuroR excision CAGCCACATTCAAAGCCATG TCCAGCAAGACCTCTCAGACC BSR excision CAGCGCACATTCAAAGCCATG TCCAGCAAGACCTCTCAGACC GGCATGGTTTTGATTTCTGGCC Copy number quantification LoxP LE CGCCCTATAGTGAGTCGTATTACA TGTTTAAATGTTTGTAGCCTGCCT				
3'-screening site late 2 for \$\textit{B}^{A}\$-qlobin+\$\textit{B}\$-actin Screening of site specific excision BSR excision at site 2 CCCCCTGAACCTGAACATAA TATCCCACTGCCACTGGAGG PuroR excision at site 3 TGCATTCTAGTTGTGTTTGTCC GGTCTGAAGGTCTTGCTGGA Large 1+3 excision Up/Low GGTCTGGTGCCCTCATTGAT TGCTCTGCTAGAATTGCCTGT chr1:72535815+72565623 Ctrl ACCCAAGGCAGGCTACAAAC TGAGTTACTTTTGGCATTACTTTTCATC chr1:72535815+72565623 Ctrl ACCCAAGGCAGGCTACAAAC TGAGTTACTTTGGCATTACTTTTCATC chr1:72565577+72567483 No PuroR excision CCCCTGAACCTGAACCTGAAACATAA GCAGCCTTTTCCAGCAAGAC No BsR excision ACGACCTTCCATGACCAGAT AGTTCTTGCAGCTAGACC PuroR excision CACGCCACATTCAAAGCCATG CACGCACACTTCAAAGCCATG TCCAGCAAGACCTCTCAGACC BsR excision CAGCGGAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAG	3'-screening site late 1 for β ^A -globin+β-actin	GAGCTCCAATTCGCCCTAT	ACTATTGTACCCCTCCCTGTTG	
BsR excision at site 2 CCCCTGAACCTGAAACATAA TATCCCACTGCACTGGAGG PuroR excision at site 3 TGCATTCTAGTTGTGGTTTGTCC GGTCTGAGAGGTCTTGCTGGA Large 1+3 excision Up/Low GGTCTGGTGCCCTCATTGAT TGCTCTGCTAGAATTGCCTGT chr1:72535815+72565623 Ctrl ACCCAAGGCAGGCTACAAAC TGAGTTACTTTTCATC chr1:72565577+72567483 No PuroR excision CCCCCTGAACCTGAAACATAA GCAGCCTTTTCCAGCAAGAC No BsR excision ACGACCTTCCATGACCGAGT AGTTTCTGCAGCTCGGTGAC PuroR excision CACGCCACATTCAAAGCCATG TCAGACCTCCAGACC BsR excision CAGCGAGACAGAGGAGAGAGGAGGAGGAGGAGGAGGAGGA	3'-screening site late 2 for BA-alobin+B-actin			
PuroR excision at site 3 TGCATTCTAGTTGTGGTTTGTCC GGTCTGAGAGGTCTTGCTGGA Large 1+3 excision Up/Low GGTTCTGGTGCCCTCATTGAT TGCTCTGCTAGAATTGCCTGT chr1:72535815+7256523 Ctrl ACCCAAGGCAGGCTACAAAC TGAGTTACTTTGGCATTACTTTTCATC chr1:72565577+72567483 No PuroR excision CCCCCTGAACCTGAAACATAA GCAGCCTTTTCCAGCAAGAC No BsR excision ACGACCTTCCATGACCGAGT AGTTCTTGCAGCTCGGTGAC PuroR excision CACGCCACATTCAAAGCCATG TCCAGCAAGACCTCTCAGACC BsR excision CAGCGGAGACAGAGGGAAGAGT GGCATGGTTTTGATTTCTGGCC Copy number quantification TGTTTAAATGTTTGTAGCCTGCCT				
Large 1+3 excision Up/Low GGTTCTGGTGCCCTCATTGAT TGCTCTGCTAGAATTGCCTGT chr1:72535815+72565623 Ctrl ACCCAAGGCAGGCTACAAAC TGAGTTACTTTGGCATTACTTTTCATC chr1:72565577+72567483 No PuroR excision CCCCCTGAACCTGAAACATAA GCAGCCTTTTCCAGCAAGAC No BsR excision ACGACCTTCCATGACCGAGT AGTTCTTGCAGCTCGGTGAC PuroR excision CACGCCACATTCAAAGCCATG TCCAGCAAGACCTCTCAGACC BsR excision CAGCGGAGACAGAGGGAGGG GGCATGGTTTTGATTTCTGGCC Copy number quantification CGCCCTATAGTGAGTCGTATTACA TGTTTAAATGTTTGTAGCCTGCCT				
Ctrl ACCCAAGGCAGGCTACAAAC TGAGTTACTTTGGCATTACTTTTCATC chr1:72565577+72567483 No PuroR excision CCCCTGAACCTGAAACATAA GCAGCCTTTTCCAGCAAGAC No BsR excision ACGACCTTCCATGACCGAGT AGTTCTTGCAGCTCGGTGAC PuroR excision CACGCCACATTCAAAGCCATG TCCAGCAAGACCTCTCAGACC BsR excision CAGCGGAGACAGAGGGAAGAGT GGCATGGTTTTGATTTCTGGCC Copy number quantification CGCCCTATAGTGAGTCGTATTACA TGTTTAAATGTTTGTAGCCTGCCT				
No PuroR excision CCCCTGAACCTGAAACATAA GCAGCCTTTTCCAGCAAGAC No BsR excision ACGACCTTCCATGACCGAGT AGTTCTTGCAGCTCGGTGAC PuroR excision CACGCCACATTCAAAGCCATG TCCAGCAAGACCTCTCAGACC BsR excision CAGCGGAGACAGAGGGAAGAGT GGCATGGTTTTGATTTCTGGCC Copy number quantification IoxP LE CGCCCTATAGTGAGTCGTATTACA TGTTTAAATGTTTGTAGCCTGCCT				
No BsR excision ACGACCTTCCATGACCGAGT AGTTCTTGCAGCTCGGTGAC PuroR excision CACGCCACATTCAAAGCCATG TCCAGCAAGACCTCTCAGACC BsR excision CAGCGGAGACAGAGGGAAGAGT GGCATGGTTTTGATTTCTGGCC Copy number quantification IoxP LE CGCCCTATAGTGAGTCGTATTACA TGTTTAAATGTTTGTAGCCTGCCT				chr1:/2565577+72567483
PuroR excision CACGCCACATTCAAAGCCATG TCCAGCAAGACCTCTCAGACC BsR excision CAGCGGAGACAGAGGGAAGAGT GGCATGGTTTTGATTTCTGGCC Copy number quantification IOXP LE CGCCCTATAGTGAGTCGTATTACA TGTTTAAATGTTTGTAGCCTGCCT				
BsR excision CAGCGGAGACAGAGGAAGAGT GGCATGGTTTTGATTTCTGGCC Copy number quantification loxP LE CGCCCTATAGTGAGTCGTATTACA TGTTTAAATGTTTGTAGCCTGCCT				
Copy number quantification CGCCCTATAGTGAGTCGTATTACA TGTTTAAATGTTTGTAGCCTGCCT				
loxP LE CGCCCTATAGTGAGTCGTATTACA TGTTTAAATGTTTGTAGCCTGCCT		ICAGCGGAGACAGAGGAAGAGI	I GGCATGGTTTTGATTTCTGGCC	
		CGCCCTATAGTGAGTCGTATTACA	TGTTTAAATGTTTGTAGCCTGCCT	
	PuroR	ACGACCTTCCATGACCGAGT	AGTTCTTGCAGCTCGGTGAC	

name	length	GC	DpnII sites/bp	Isample	total interactions	cis percent
allele1+3	2532	56.7	0.0043	clone 4	2433	67.41
allele1+3	2532	56.7	0.0043	clone 5	2369	69.78
allele2	2509	46.2	0.0032	clone 4	1318	80.2
allele2	2509	46.2	0.0032	clone 5	1290	78.53
chr1	196202544	40	0.0021	clone 4	121564119	81.08
chr1	196202544	40	0.0021	clone 5	116517761	80.63

Appendix Figure S1: Quantitative analysis of RT shifts by two distinct calculation methods reveals cooperation between two combinations of *cis*-regulatory elements

A. Method for allele-specific analysis of RT by real-time PCR quantification. BrdU pulse-labeled cells were sorted into four S-phase fractions (S1 to S4) and the immunoprecipitated newly synthesized strands (NS) were quantified by real-time qPCR in each fraction. Specific primer pairs determine the RT profile for the modified allele (With), the wt allele (Without) and both alleles (Both). The endogenous β -globin locus was analysed as an early-replicated control.

B-C. Two methods of calculation were used to determine the difference in RT between the wt and modified alleles: the - ΔL + ΔE method and the ΔS lope method.

D. The analysis of the correlation between the Δ Slope and the - Δ L+ Δ E method for all clonal cell lines previously published (Hassan-Zadeh et al., 2012; Valton et al., 2014) or analysed for the first time here is shown. The linear regression curve is shown, with the corresponding equation and the coefficient of determination (R²).

Appendix Figure S2: Endogenous genomic features of early-replicated domains containing the β globin and β -actin loci

A-B. UCSC genome browser visualization (galGal5) of 4 Mb genomic windows inside either the β -globin locus of chromosome 1 or the β -actin locus of chromosome 14 are shown. Annotated genes are represented and the β - β -globin and the β -actin genes are indicated by a red arrow. Track of eigenvector 1 values corresponding to A/B compartments at 25 kb resolution after Hi-C analysis are represented. Tracks of nascent strands (NS) enrichments obtained after cells sorting into four S-phase fractions, BrdU pulse-labeled nascent strands (NS) immunoprecipitation, and sequencing were represented separately (S1 to S4) for the wt cell line in dense configuration. Below, an enlargement of either the β -globin or the β -actin promoter region with the ectopic sequence found in our constructs and the single reads from SNS aligned previously published (Massip et al., 2019) are reported.

Appendix Figure S3: P-value distribution for the effect of the β^A -globin + β -actin construct on RT in the mid-late locus

A. Replication timings of the WT and the $2x(\beta^A-globin + \beta-actin)$ insert were smoothed using 500kb sliding windows, then centered and normalized so that the variability of timings were comparable between the two conditions.

B. A t-test was performed for each window to assess the significance of the timing differences. Adjusted p-values were computed for each window and smoothed using the PLIS R-package (Wei et al., 2009) to account for their spatial genomic dependency. P-values were then adjusted by the Benjamini-Hochberg procedure to ensure the control of the False Discovery Rate. The dotted line corresponds to a FDR of 5%.

Appendix Figure S4: Interaction profiles of allele 1+3/2 with chromosome 1 for clones 4 and 5

A. Interaction profiles of allele 1+3/2 with chr1 for clone 4 Hi-C libraries: distance-corrected interactions, *i.e.* observed/expected (OE), binned at 500 kb with corresponding compartment (EV1) tracks.

B. OE interactions of allele 1+3 (orange rectangles) and allele 2 (blue rectangles) averaged over A and B compartments for p and q-arms at 100kb bin size for clone 4. Values corresponding to OE interactions of allele 1+3 and allele 2 averaged over shuffled A (red circles, N=1000) and B compartments (blue circles, N=1000) for p and q-arms. ns, not significant; *p<0.05; **p<0.01;***p<0.001.

C. Scatterplot of density of interactions between allele 1+3 and allele 2 with chromosomes larger than 5,000,000 bp for clone 4.

D. Interaction profiles of allele 1+3/2 with chr1 for clone 5 Hi-C libraries: distance-corrected interactions, *i.e.* observed/expected (OE), binned at 500 kb with corresponding compartment (EV1) tracks.

E. OE interactions of allele 1+3 (orange rectangles) and allele 2 (blue rectangles) averaged over A and B compartments for p and q-arms at 100kb bin size for clone 5. Values corresponding to OE interactions of allele 1+3 and allele 2 averaged over shuffled A (red circles, N=1000) and B compartments (blue circles, N=1000) for p and q-arms. ns, not significant; *p<0.05; **p<0.01;***p<0.001.

F. Scatterplot of density of interactions between allele 1+3 and allele 2 with chromosomes larger than 5,000,000 bp for clone 5.

Appendix Figure S5: Validation of MNase digestion patterns before and after size selection (Related to Figure 6 and EV4)

A-B. Chromatin was extracted from two clonal cell lines for each construct or combination (β^A -globin, β -actin, β^A -globin+ β -actin, 1+2+3, 1+3 and loxP_LE (1)+ β^A -globin+ β -actin (3) and partially digested with exponentially increasing concentrations of micrococcal nuclease (MNAse; 2.5, 10, 40 and 160 U/mL).

A. After purification, DNA molecules were subjected to a size selection process that removed most DNA molecules over 1000 bp.

B. The four digested DNA samples obtained for each clonal cell line were subjected to electrophoresis in a 1% w/v agarose gel before and after size selection and stained with SYBR safe. The DNA size marker was a commercial 1 kb plus ladder.

Appendix Figure S6: Validation of the semi-quantitative PCR approach used to determine the spatial proximity of different combination of *cis*-regulatory elements separated by 30 kb (Related to Figure

A-B. Images of agarose gels used for the quantification of specific products obtainted after either the large 1+3 and $loxP_LE$ (1)+ β^A -globin+ β -actin (3) excision in 1+2+3, 1+3 and $loxP_LE$ (1)+ β^A -globin+ β -actin (3) clonal cell lines or the large β -actin (1+3) excision in β -actin (1+3) clonal cell line are shown. After 1, 8, 24 and 48 h of 4-hydroxytamoxifen treatment, genomic DNA was extracted and quantified by semi-quantitative PCR. PCR products specific for the large 1+3 or $loxP_LE$ (1)+ β^A -globin+ β -actin (3) excision (3.4 kb, in a thick black lines, Up and Low large excision, A left gels), and for the large β -actin (1+3) excision (542 bp, in a thick black lines, Up and Low large excision, B left gels) or used for normalization (1.9 kb, amplification from both chromosomes, in a thick black line, Ctrl, A and B right gels) were run on a 0.8% or 1% w/v agarose gel, respectively, and stained with SYBR safe. The DNA size marker was a commercial 1 kb plus ladder.

Appendix Figure S7: PCR validation of clones selected for homologous recombination

A-H. Schematic diagrams showing genomic region containing a site-specific integrated construct. The 5' and 3' arms of the targeted vector are shown as black boxes. Arrows #1 and #2 represent primer sets used for the analysis of correct integration of the constructs by homologous recombination. Other arrows represent primer sets used for the analysis of the correct excision of the *BsR* gene at site 2 (#3 and #4) or the correct excision of the *PuroR* gene at site 3 (#5 and #6). PCR products were subjected to electrophoresis in a 1-1.5% w/v agarose gel and stained with SYBR safe. The DNA size marker was a commercial 1 kb plus DNA ladder (M). Lanes marked with a red star correspond to clonal cell lines selected for further analysis.

A-C. Insertion site 1, containing the β -actin construct, one $loxP_LE$ element or the β ^A-globin+ β -actin construct is shown.

D. Insertion site 2 containing the *GFP* reporter construct is shown.

E-F. Insertion site 3, containing the β^A -globin+ β -actin or the β -actin construct construct is shown.

G-H. The two genomic regions containing the β^A -globin+ β -actin construct inserted at the late 1 or late 2 site are shown.

A-H. The sizes of the different PCR products obtained after amplification with primers #1 and #2, to check for correct integration, are 2.4 kb (A), 2.6 kb (B), 2.3 kb (C), 2.6 kb (D, left gel), 2.3 kb (E except the last right gel), 2.9kb (F), 2.6 kb (G) and 2.2 kb (H). The sizes of the different PCR products for the screening of cell lines correctly recombined for the BsR gene cassette after amplification with primers #3 and #4 are 2.1 kb (D, insertion site 2, right gel) or 1.2 kb with the primers #5 and #6 (F, insertion site 3, last right gel). The clonal cell line containing the GFP reporter construct without the BsR cassette at site 2 (D, 1-BsR) was used for further insertions at site 1 (B, #2 and C, #3 to #6) or at site 3 (E, #1 to #4). The clonal cell lines containing the GFP reporter construct without the BsR cassette at site 2 and one autonomous replicon at site 1 (C, #3, #4, #5) were used for further insertions at site 3 (E #5 to #9). The clonal cell lines containing the GFP reporter construct without the BsR cassette at site 2 and one loxP_LE at site 1 (B, #2) were used for further insertions of an autonomous replicon at site 3 (E, #10 to #12). Clone 1 with the β^A -globin construct inserted at site 1, as previously obtained (Hassan-Zadeh 2012, Fig.6B), was used for the further insertion of a β^{A} globin+ β -actin construct at site 3 (E #13 to #18). Clonal cell lines containing two minimal β^A -globin modules at sites 1 and 3 were obtained after excision of the *PuroR* cassette at site 3 (E, -*PuroR*, #13 to 18). Clone 2 with the β -actin construct inserted at site 1 (B, #2) was used for further insertions of the β -actin construct at site 3 (F, #19 to #23).

Appendix Figure S8: Validation of transgene integration into the same chromosome

A. The insertion of transgenes into the same or a different chromosome was analyzed by long-range PCR, with a primer set composed of an upstream primer binding within one construct and a downstream primer binding to the other construct. The amplicons generated after PCR amplification to test for insertion into the same chromosome are represented by red arrows (LR1+2, LR2+3, LR1+3, LR loxP_LE (1)+ β^A -globin+ β -actin (3), LR β^A -globin (1+3), LR β -actin (1+3)). The absence of an amplicon indicates that the two constructs were inserted into distinct chromosomes. The quality of the DNA was checked with primer sets amplifying, on the two chromosomes, a genomic region located between the two insertion sites (black arrows, LR 1+2 ctrl, LR 2+3 ctrl, LR 1+3 ctrl).

B. PCR products were subjected to electrophoresis in a 0.8% w/v agarose gel and stained with SYBR safe. The DNA size marker used was a commercial 20 kb plus ladder. 1+2 clonal lines #3 and #4 were used to generate 1+3 clonal lines #1 and #2 with the *GFP* reporter construct inserted at site 2 on the same chromosome and 1+2 clonal line #2 was used to generate 1+3 clonal lines #3 to #5 with the *GFP* reporter construct inserted at site 2 on the other chromosome. Clonal line with the *GFP* reporter construct inserted at site 2 was used to generate one clonal line with the *loxP_LE* element inserted at site 1, which itself generated $loxP_LE$ (1)+ β^A -globin+ β -actin (3) clonal lines #1, #2 and #3 with the *GFP* reporter construct inserted at site 2 on the other chromosome. Clonal line 1 with the β^A -globin construct inserted at site 1, as previously obtained (Hassan-Zadeh 2012, Fig.6B), was used to generate β^A -globin (1+3) clonal lines #1 to #6. Clonal line with the β -actin construct inserted at site 1 was used to generate β -actin (1+3) clonal lines #1 to #5.

Appendix Figure S9: Additional filtering of Hi-C interactions

A. Heatmap of interaction frequencies for p-arm of chr1, demonstrating the position of the insertion site (red arrow) relative to filtered translocations (blue arrows).

B. Raw and unfiltered interactions profiles for allele 1+3 and allele 2 with chr1 p-arm, observed in two clones and their combination, with the corresponding EV1 compartment track. Translocations are highlighted on the compartment track with light blue color and with blue arrows. The insertion site is highlighted with a red arrow.

C-D. Raw and unfiltered interactions profiles for allele 1+3 and allele 2 with chr1 and chr9, observed in two clones and their combination. Blue arrow indicates the location of the β^A -globin promoter.

Table 1: Summary of all clonal cell lines (previously published or new clonal lines) analysed in this study

Table 2: Transgene copy number determination in clonal cell lines

The table shows the qPCR results obtained with genomic DNA extracted from the clones selected for the experiments. For each clone, 2 ng of genomic DNA was amplified with a primer set amplifying a sequence within the construct (With) and another primer set amplifying a sequence 5 kb downstream from the insertion site for both alleles (Both). The ratio of the amounts of DNA obtained with the With and Both primer sets was used to determine transgene copy number in all clonal cell lines. For each line, the construct for which the copy number was tested is indicated with the corresponding insertion site.

Table 3: Primers sets used for plasmids constructions

Table 4: Primer sets used for quantitative PCR

Table 5: Characterization of the reference sequences of allele 1+3/2

Characterization of the sequences of allele 1+3 and allele 2 inserts and raw interactions involving the inserts obtained from Hi-C experiments for clones 4 and 5. Characterization of the entire chr1 is added as a reference.

References

Hassan-Zadeh, V., Chilaka, S., Cadoret, J.-C., Ma, M.K.-W., Boggetto, N., West, A.G., and Prioleau, M.-N. (2012). USF binding sequences from the HS4 insulator element impose early replication timing on a vertebrate replicator. PLoS Biol. *10*, e1001277.

Massip, F., Laurent, M., Brossas, C., Fernández-Justel, J.M., Gómez, M., Prioleau, M.-N., Duret, L., and Picard, F. (2019). Evolution of replication origins in vertebrate genomes: rapid turnover despite selective constraints. Nucleic Acids Res. 47, 5114–5125.

Valton, A.-L., Hassan-Zadeh, V., Lema, I., Boggetto, N., Alberti, P., Saintomé, C., Riou, J.-F., and Prioleau, M.-N. (2014). G4 motifs affect origin positioning and efficiency in two vertebrate replicators. EMBO J. *33*, 732–746.

Wei, Z., Sun, W., Wang, K., and Hakonarson, H. (2009). Multiple testing in genome-wide association studies via hidden Markov models. Bioinformatics *25*, 2802–2808.